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Background: Schizophrenia is a severe mental disorder that manifests in positive and negative 
symptoms, and cognitive deficits. The disturbance of synchronous network activity that is 
maintained by the balanced interplay between excitatory pyramidal neurons and inhibitory 
interneurons is implicated in schizophrenia. At the molecular level, an activated Neuregulin-
ERBB4 pathway impacts on disrupting the excitation-inhibition (E/I) balance. Conversely, 
decreasing enhanced ERBB4 activity may restore the E/I balance. 
Results: In a cell-based assay using the split TEV technology, we screened FDA-approved drugs 
that antagonize ERBB4 activity. Spironolactone was recovered as best candidate from the 
screen and was validated to reduce phosphorylation levels of ERBB4 using biochemistry. 
Together with the findings from electrophysiology and mouse behavior studies, we concluded 
that spironolactone improves the E/I balance by decreasing ERBB4 phosphorylation. However, 
spironolactone is not selective for ERBB4 among the ERBB family. To address selectivity, a 
universal RTK adapter suitable for cell-based high-throughput screening assays was designed. 
The clustered SH2(GRB2) domain adapter increased the comparability of RTK assays and 
allowed to better assess compound selectivity across targets.  
Outlook: Using RNA barcode reporters we can monitor the activity of multiple targets and 
pathways simultaneously. Using such a multiplexing approach, we will be able to profile 
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Schizophrenia is a mental syndrome that influences feelings, behavior, and cognition of a 
person. The symptoms can be classified into three groups. 1) Positive symptoms, like 
hallucinations and delusions; 2) negative symptoms, such as anxiety and loss of motivation; 
and 3) cognitive impairment, including memory function and attention span. The symptoms 
typically appear gradually, starting in adolescence and, in most cases, never resolve (van Os 
and Kapur, 2009). The prevalence in the world’s population is between 0.3% and 0.7% (Saha 
et al., 2005). Schizophrenia is a complex disease, meaning that a genetic burden contributes 
together with environmental factors to the outbreak and severity. This complexity is 
represented in the “Two-Hit” hypothesis of schizophrenia (shown in figure T1) (Bayer et al., 
1999). It states that there is first a hit of neurodevelopmental alterations based on the genetic 
load, leaving the neuronal circuitry vulnerable to the second hit of environmental factors later 
in life (Insel, 2012; Rapoport et al., 2012). There is some evidence of neurobiological 
alterations in schizophrenia like reduced connectivity (Schmitt et al., 2011) and thinner cortical 
structures (Shaw et al., 2007). However, unlike the neuronal degeneration in Alzheimer’s 
disease or the specific lesion in the substantia nigra in Parkinson’s, schizophrenia does not 
have a single neurobiological cause (Maynard et al., 2001). Instead, the pathological 
mechanisms remain mostly unclear and are subject to current research and hypotheses. 
Despite scientific progress and knowledge about schizophrenia, new treatments, especially of 
the negative and cognitive symptoms, have not been developed in the past years (Insel, 2012). 
 
Figure T1: Two Hit Model of Schizophrenia suggests that disruptions in the first hit the 
development of the central nervous system (CNS) produce a vulnerability to the disorder but 
that the onset of symptoms in a vulnerable brain would be triggered by the second hit of 
environmental factors. Adapted from (Maynard et al., 2001).  
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Genetics of Schizophrenia 
 
Schizophrenia has a high heritability of around 60-80% as shown by twin and family studies 
(Lichtenstein et al., 2009; Sullivan et al., 2003). To study the genetic loci behind this heritability 
so called genome-wide association studies (GWAS) are conducted. In GWAS, a genome-wide 
set of genetic variants, specifically single-nucleotide polymorphisms (SNPs), in different 
individuals are observed and a case versus control comparison is made. The advantage of 
GWAS is that it is not hypothesis driven. The SNPs tested are spread all over the genome and 
do not necessarily lie in a coding region of a gene. The latest GWAS in schizophrenia identified 
145 risk loci from a meta-analysis integrating the results from a study including up to 36,989 
cases compared to 113,075 controls (Schizophrenia Working Group of the Psychiatric 
Genomics Consortium, 2014) and further 11,260 independent cases and 24,542 controls 
(Pardiñas et al., 2018). This means schizophrenia is a highly polygenic disease. As a biological 
marker is lacking the cohorts are grouped functionally with symptoms and science. This big 
aetiological heterogeneity is overcome by the high case numbers used in GWAS. The most 
relevant genetic factors are identified due to the large cohort numbers providing high 
statistical power. Therefore, a higher reproducibility than in the older more hypothesis driven 
genetic studies is achieved. In the loci presented are both, risk genes that have not been 
associated with schizophrenia before, and genes where an association to the disease has been 
discussed previously. Examples for the latter case are the dopamine D2 receptor (DRD2) and 
a subunit of the N-methyl D-aspartate (NMDA) type glutamate receptor called glutamate 
ionotropic receptor NMDA type subunit 2A (GRIN2A) (Pardiñas et al., 2018). The strongest 
genetic association involves major histocompatibility complex variations, arising from 
structurally diverse alleles in the complement component 4 (Schizophrenia Working Group of 
the Psychiatric Genomics Consortium et al., 2016). Additionally, the GWAS shows suggestive 
evidence by weaker genetic association for the Neuregulin 1 (NRG1)- erb-b2 receptor tyrosine 
kinase 4-(ERBB4) pathway that was one of the first pathways that has been connected to 
schizophrenia (Balu and Coyle, 2011; Mei and Nave, 2014; Schizophrenia Working Group of 





Theories for the pathoaetiology of schizophrenia 
 
An early theory about the neurobiological causes of schizophrenia symptoms is linked to the 
DRD2 risk gene and is called the dopamine theory. It was created on the basis of finding that 
an inhibition of DRD2 reduced positive symptoms in mice (Carlsson and Lindqvist, 1963). Other 
studies showed that the effects of antipsychotic drugs in the clinic correlated with their 
dopamine receptor affinity (Creese et al., 1976; Seeman and Lee, 1975). However, negative 
and cognitive symptoms could not be explained using this initial model. 
As a general idea of the mechanisms and pathways behind the disease was lacking, the 
hypothesis was reverse engineered from the treatable targets, the dopaminergic mechanism 
in the brain (Meltzer and Stahl, 1976). This interpretation of evidence led to limitations in the 
hypothesis. The drugs used, in addition to their effect on dopamine, alters the signaling of 
other neurotransmitters (Davis et al., 1991). Additionally, the locus in the brain where the 
dopaminergic signaling was altered was not known at the time. Finally, the theory was only 
able to explain the positive symptoms of the disease. Nevertheless, the dominant theory 
strongly influenced the search for treatments towards the dopaminergic mechanisms in the 
prefrontal cortex (Schwartz et al., 2012). Subsequently, antipsychotic drugs form the mainstay 
in schizophrenia treatment today (Andrews et al., 2003).  
With the dopamine theory as a basis, and its limitations apparent, the hypothesis has been 
extended by the glutamate theory. It was shown that antagonists of NMDA type glutamate 
receptors (NMDARs) , such as ketamine or phencyclidine, could induce all three symptom 
groups (Coyle, 2012; Javitt, 2010). While the dopaminergic transmitters are a regionally 
distinct system, NMDARs are expressed all over the brain. The glutamate theory therefore 
incorporates alterations connected to schizophrenia also in the cortex and subcortical regions. 
At first, a glutamatergic neurotransmission deficit was postulated. Over the years, the theory 
has been developed further and many glutamate receptors were linked to the theory; 
however, the primary involvement of dysfunctional NMDA receptor prevailed (Stone et al., 
2007) a finding that is supported by the candidate risk gene GRIN2A, a NMDAR subunit 
(Pardiñas et al., 2018). Additionally, alterations to glutamatergic functioning were found in 
post-mortem studies. For example, expression of glutamate receptors, especially the levels of 
the subunit NMDAR1 in the superior frontal cortex as well as the superior temporal cortex 
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were shown to be reduced (Humphries et al., 1996; Sokolov, 2002). These findings have, 
however, been inconsistent. The problem seems not to be caused by the general expression 
level, but rather in an altered localization of the NMDA receptor (E. McCullumsmith et al., 
2012; Hammond et al., 2014). This irregular trafficking could arise from changes that target 
proteins involved in the trafficking process itself, or the binding capacities between NMDARs 
and these auxiliary proteins (Funk et al., 2009).  
The two theories do not contradict and could therefore both play a role in the neurological 
cause of schizophrenia. The activity of dopaminergic neurons is regulated by the projections 
of glutamatergic neurons to the dopamine nuclei in the midbrain. These nuclei, therefore are 
sensitive to both changes of the glutamatergic and dopaminergic signaling (Mcguire et al., 
2008; Miller and Abercrombie, 1996). 
Given the already discussed variety of loci found in the GWAS to be involved in Schizophrenia, 
and the complexity that arises from the aforementioned theories of pathoaetiology it is 
unlikely that schizophrenia and its symptoms in all cases arise from a single cause (Horváth 
and Mirnics, 2015; Howes and Kapur, 2014). 
Both theories are reverse engineered from findings that drugs induce or reduce symptoms of 
schizophrenia. This approach is relevant as it does show a druggable target of the disease 
immediately. As mentioned, most of the drugs used for schizophrenic patients are addressing 
the positive symptoms of the disease. The search for new druggable targets, especially for the 





Neurodevelopmental causes of Schizophrenia 
Schizophrenia today is seen as a neurodevelopmental disease (Insel, 2010). The variety of 
genetic alterations influences the development of the central nervous system (CNS) right from 
its start. For example, there is evidence for NMDAR alterations to play a role in various 
developmental issues in the CNS. The formation of dendritic spines and growth of dendritic 
trees is disrupted by NMDAR hypofunction (Monfils and Teskey, 2004; Sin et al., 2002). The 
myelination of axons is also affected, here by the alteration of NMDARs through neuregulin 1 
(NRG1) and brain-derived neurotrophic factor (BDNF) (Lundgaard et al., 2013). This implies 
that white matter changes can be a consequence, not a cause, of diverging synaptic plasticity 
by modulations of the NMDA receptors. However, there is currently some debate whether 
myelination factors may also play an active role in eliciting schizophrenia (Raabe et al., 2018). 
This argumentation opens schizophrenia research up for neurogenetic connectivity studies. In 
bipolar disorder for example, descending connectivity from the prefrontal cortex and its 
selective failure has already been shown (Radua et al., 2013). Understanding the importance 
of NMDAR signaling in schizophrenia patients and in CNS development, a theory was 
developed, not only reverse engineered from the effects of different drugs, but also based on 
a top-down theory of how we perceive the world in general. This model integrates 
schizophrenia-relevant brain structures, such as the nucleus accumbens and prefrontal cortex, 
and was connected to the three symptom classes. 
Predictive coding and the disconnection hypothesis  
The disconnection hypothesis of schizophrenia is based on the idea that the brain is a 
statistical Bayesian organ. It generates hypotheses of what sensory input will be received and 
tests these against the sensory evidence. This paradigm has already been proposed by 
Helmholtz with the idea of unconscious interference (Helmholtz, 1866). Over time, the 
perspective has been developed to include the causes of our sensations as hierarchical 
Bayesian interference and the way these interferences generate beliefs and behavior (Clark, 
2013; Dayan et al., 1995; Friston et al., 2006; Lee and Mumford, 2003). 
Predictive coding means that higher levels of cortical hierarchies create predictions of 
representations and compare them to the representations coming from lower levels, a 
scheme is presented in figure T2. The representations from lower levels initially come from 
the sensory input. The difference between these two representations is manifested as 
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prediction error, which is associated with superficial pyramidal cells and their activity. The 
prediction error is transmitted back up in the hierarchy, to enable the generation of an 
updated higher representation, a process connected to deep pyramidal cells and their activity. 
This recursive transition leads to a shrinking of the prediction error until its suppression, with 




Figure T2: This figure summarizes the neuronal message passing that underlies predictive 
coding. The basic idea is that neuronal activity encodes expectations about the causes of 
sensory input, where these expectations minimize prediction error. Prediction error is the 
difference between (ascending) sensory input and (descending) predictions of that input. This 
minimization rests upon recurrent neuronal interactions between different levels of cortical 
hierarchies. Anatomical and physiological evidence suggests that superficial pyramidal cells 
(grey triangles) compare the representations (at each level) with top-down predictions from 
deep pyramidal cells (black triangles) of higher levels. This schematic shows a simple cortical 
hierarchy with ascending prediction errors and descending predictions. This graphic includes 
neuromodulatory gating or gain control (dotted lines) of superficial pyramidal cells that 
determines their relative influence on deep pyramidal cells encoding expectations (in the 
same level and the level above). Note that the implicit descending gain control rests on 
predictions of the precision of prediction errors at lower levels – and can be thought as 
mediating top-down attentional gain. Every top-down prediction is reciprocated with a 
bottom-up prediction error to ensure predictions are constrained by sensory information. 





The recursive ascending and descending signaling is mostly mediated by NMDARs. The 
disconnection hypothesis combines the predictive coding approach with the importance of 
NMDAR signaling and the known defects observed in schizophrenia patients. The 
disconnection hypothesis specifically emphasizes the role of transmitters and proteins that 
modulate NMDAR localization. These modulations then lead to alterations in synaptic efficacy. 
For example, NMDAR conductivity may be altered via phosphorylation, subunit expression, 
and trafficking (Stephan et al., 2009). Importantly, the disconnection hypothesis describes the 
physiological consequences of NMDAR mediated plasticity and how these transfer into 
impairment of computation in the neuronal circuits (Friston et al., 2016). 
The excitation inhibition balance 
During predictive coding, coordination of activity of the individual brain regions, layers, and 
neurons is key (Miller and Cohen, 2001). This coordination is achieved by synchronous 
inhibition of pyramidal neurons (Gonzalez-Burgos et al., 2010), a process referred to as the 
excitation-inhibition balance (E/I balance). When excitation surpasses inhibition, activity will 
increase to the maximum, or when inhibition is induced by this maximum, network activity 
will lead to a balanced state. The same holds true for inhibition surpassing excitation, either 
quieting the circuit or sparking more excitation in the process, again leading to a balanced 
activity in the network (Sohal and Rubenstein, 2019). It was shown that in cortical layer 2/3 
optimal tuning of E/I balance produced neuronal activity responses that are referred to as 
neuronal avalanches and optimized information processing in the network (Shew et al., 2011). 
This crucial balance is mainly mediated by parvalbumin-positive (PV-positive) GABAergic 
interneurons (Cardin et al., 2009; Sohal et al., 2009) that themselves are connected to 
glutamatergic neurons as input and output. These connections form a so-called microcircuit 
shown in figure T3. This simplified version shows how a glutamatergic neuron excites a 
downstream glutamatergic neuron and an inhibitory neuron that subsequently can inhibit the 
activity of the second glutamatergic neuron. In reality, glutamatergic neurons receive input 
from a variety of inhibitory and excitatory neurons, which themselves are connected to a 
variety of functionally diverse neurons (Elert, 2014; He and Cline, 2019). The number of 
neurons involved in the E/I balance is highly regulated, as is the number of synapses on 
individual cortical pyramidal neurons (Hengen et al., 2013; Iascone et al., 2018). 
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Interneurons are important for the E/I balance that matures until adolescence, a timeframe 
correlating with the outbreak of schizophrenia (Insel, 2010). While there is little evidence 
coming from human adolescent post-mortem neuroanatomy, studies in nonhuman primate 
brains show that during early adulthood the refinement of circuits involves pruning of 
excitatory synapses, inhibitory circuit maturation, and continuous targeting of pyramidal 
dendrites by inhibitory input (Hashimoto et al., 2009; Lewis and González-Burgos, 2008; Rakic 
et al., 1986). 
In summary, interneuron activity is crucial for the functioning of the neuronal network as it 
synchronizes excitatory neuronal activity through inhibition. The expression of the NMDA 
receptors, which are responsible for transmission of the glutamatergic signal are unchanged 
in Schizophrenia patients. Subsequently the focus of attention, as described in the 
disconnection hypothesis lies on mechanisms that modulate the E/I balance. One of the 





Figure T3: Example of a microcircuit and its impact on schizophrenia. (1) Principle neuron fires 
and generates electric pulse; signal arrives at synapse releasing glutamate (2); glutamate binds 
to receptor on GABAergic interneurons, in schizophrenia this connection is abnormal, 
decreasing the interneuron activity (3). (4) Activity of the second glutamate neuron is 
increased due to decreased GABAergic inhibition (5), at the synapses (6) too much glutamate 
is released, overstimulating a dopaminergic neuron. (7) GABA interneuron over inhibits a 
different dopaminergic neuron suppressing its activity. Resulting in (8) a decreased 
dopaminergic neuronal signal to the prefrontal cortex, leading to negative symptoms. (9) 






The NRG1-ERBB4 Pathway 
The NRG1-ERBB4 Pathway is associated with several functions in the developing and matured 
brain. As it is specifically connected to synaptic maturation and plasticity it is connected to 
several psychiatric disorders, such as autism, bipolar disorder and schizophrenia (Kenny et al., 
2014; Mei and Nave, 2014). The combination of NMDAR hypofunction only in PV interneurons 
and subsequent increase in glutamatergic signaling and how that influences the E/I balance 
brings the NRG1-ERBB4 pathway into focus for schizophrenia as seen in the disconnection 
hypothesis. Notably, ERBB4 is selectively expressed in PV interneurons (Fazzari et al., 2010; 
Vullhorst et al., 2009). 
ERBB4 is a receptor tyrosine kinase (RTK) and together with EGFR, ERBB2 and ERBB3 belongs 
to the ERBB sub-family of RTKs (Lemmon and Schlessinger, 2010). NRG1 is a trophic factor that 
contains an epidermal growth factor (EGF) like domain and belongs to the neuregulin family 
that acts on the ERBB family as ligands for activation (Britsch, 2007). RTKs and their signaling 
will be described in more detail later in this introduction. 
It has been shown that ERBB4, when activated, associates with NMDA receptors leading to an 
internalization of both receptors. Subsequently, NMDAR, but not α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptor, currents are downregulated (Vullhorst et 
al., 2015). NRG1 acutely dampens the excitability of Erbb4-expressing interneuron by 
depolarizing the firing threshold (Janssen et al., 2012). Additionally, ERBB4 splicing patterns 
are involved in the regulation of excitatory synapse formation onto PV interneurons (Chung 
et al., 2016, 2017, 2018). ERBB4 is specifically expressed in PV interneurons, while NRG1 
maybe expressed both pre- and post-synaptic (Vullhorst et al., 2017) and personal 
communication with Markus Schwab) In agreement, NRG1 overexpression and NMDAR 
hypofunction in PV interneurons has been connected to schizophrenia symptoms recently 
(Bygrave et al., 2019; Kotzadimitriou et al., 2018). In an in vivo study on healthy subjects GABA 
concentrations were predicted by genetic variation in ErbB4 (Marenco et al., 2011).  
In addition, an increased expression of NRG1 was found in schizophrenia patients in a number 
of postmortem studies (Hashimoto et al., 2004; Law et al., 2006; Weickert et al., 2012). 
In line with these findings, a hyperphosphorylation of ERBB4 was also found in postmortem 
brains in schizophrenia patients (Hahn et al., 2006). Furthermore, increased expression of the 
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ERBB4-JM-a-CYT-1 variant carrying a PI3K-recruitment domain has also been detected in 
schizophrenics (Silberberg et al, 2006; Law et al, 2007, 2012), supporting the notion that the 
NRG1-ERBB4 signaling is elevated in patients. Nrg1-Erbb4 signaling is also increased during 
neuronal activity linked to limbic seizure (Tan et al., 2012) and spontaneous seizures are 
increased when Erbb4 is lost in PV Interneurons promoting kindling progression (Li et al., 
2012b; Tan et al., 2012). All these findings show that the NRG1-ERBB4 pathway is regulating 
NMDAR function and hence plays a role in the E/I balance. 
NRG1-ERBB4 signaling also plays a role in the development of the brain, specifically in different 
stages of circuit development in the cortex (Mei and Nave, 2014). The migration of 
interneurons during the development of the cortex is regulated by NRG1 (Flames et al., 2004; 
Li et al., 2012a). Erbb4 mutant mice show reduced amounts of GABAergic interneurons in the 
cortex, it is however unclear if genesis and/or survival of those interneurons are changed. 
Synapse formation in cortical circuits is also connected to NRG-ERBB signaling. The generation 
and maturation of excitatory synapses signaling on to GABAergic interneurons is promoted 
(Abe et al., 2011; del Pino et al., 2013; Ting et al., 2011). Transgenic mice with increased Nrg1 
expression show schizophrenia relevant behavioral deficits, such as hyperactivity, decreased 
sensorimotor gating, impaired social interaction, and reduced cognitive functions (Deakin et 
al., 2009, 2012; Kato et al., 2010). Schizophrenia risk genes are known to cause overlapping 
behavioral and synaptic plasticity phenotypes both at gain and loss function, as exemplified 
for transcription factor 4 (TCF4), which is one of the best replicated risk genes for 
schizophrenia (Badowska, 2015; Brzózka et al., 2010). Likewise, reduced and elevated NRG1 
levels in cortical projection neurons lead to reduced synaptic plasticity and impaired inhibitory 
neurotransmission, arguing that NRG1 levels need to be maintained at an optimal level to 
guarantee a balanced excitatory and inhibitory neurotransmission (Agarwal et al., 2014). 
In summary, these findings suggest that the NRG1-ERBB4 risk pathway plays a role in 
schizophrenia pathophysiology, likely by influencing PV interneuronal signaling and thus 
altering the E/I balance. 
Elucidating the mechanisms regulated by the NRG1-ERBB4 pathway is not only central to 
understanding the basis of schizophrenia but will be also useful for the treatment of the 
disease, as ERBB4 as a receptor is a druggable target. It is for example speculated, that 
treatments to increase NMDAR function, e.g. by decreasing ERBB4 activity, could reduce 
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oxidative stress and boost the function of PV interneurons and therefore might be beneficial 
for schizophrenia (Powell et al., 2012). In mouse studies it has been shown that 
endophenotypes caused by increased NRG1 levels are reversible in adult animals. This 
indicates that NRG1-ERBB4 signaling could principally function as a target for pharmacological 
intervention in patients (Luo et al., 2014; Yin et al., 2013). As impaired NRG1-ERBB4 signaling 
is implicated in all three symptom classes of schizophrenia (Agarwal et al., 2014; Luo et al., 
2014), a pharmacological intervention might be beneficial through optimizing the E/I balance. 
In general, the need to explore new targets and develop directed therapies for schizophrenia 
is high (Nestler and Hyman, 2010). Many Pharma companies have withdrawn from research 
on severe mental disorders due to the complex nature and the still limited mechanistic 
understanding of these diseases (Margraf and Schneider, 2016). As already mentioned current 
medication is mostly targeting the positive symptoms of schizophrenia (Insel, 2012). 
Additionally, drug development campaigns for drugs targeting the negative symptoms have 
failed, for example the clinical trials for bitopertin (Bugarski-Kirola et al., 2017). One of the 
options could be to use drug repurposing, where already approved drugs are monitored for 
additional or different usage, presenting a swift way towards clinical application (Insel, 2012; 
Lencz and Malhotra, 2015). In conclusion, there is a need to develop better and more specific 
assays to find drugs and monitor their efficacy and side effects. 
 
The ERBB family is a subfamily of receptor tyrosine kinases 
There are 58 receptor tyrosine kinases known in humans, the kinases can be divided into 20 
sub families, one of which is the ERBB sub family (Lemmon and Schlessinger, 2010). RTKs are, 
together with G protein coupled receptors (GPCRs), one of two most important drug targets 
in human cells (Santos et al., 2017). When RTKs are stimulated, they dimerize as homo or 
hetero dimers restricted to their sub family. Dimerization leads to a kinase domain-mediated 
cross phosphorylation of the phosphotyrosine (p-Tyr) motifs present in the cytoplasmic 
receptor. Upon phosphorylation, an adapter is recruited binding to those phosphorylated p-
Tyr motifs. To bind, the adapter needs a Src homology 2 (SH2) domain or a phosphotyrosine-
binding (PTB) domain (Yaffe, 2002). There are 120 different SH2 domains in 110 different 
proteins, making this the largest class of p-Tyr recognition domains (Liu et al., 2006), with the 
most important ones for the ERBB family being Phosphatidylinositol 3-kinase regulatory 
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subunit alpha (PIK3R1), SHC-transforming protein 1 (SHC1), and Growth factor receptor-
bound protein 2 (GRB2). The specificity of binding between different receptors and adapters 
is important for the initiation of specific downstream signaling and correlates to the selectivity 
of receptor activity (Davis et al., 2011). This specificity is caused by the interplay between the 
amino acid residues sequence flanking the tyrosine of the p-Tyr motif and the residues in the 
SH2 domain itself. Their interaction and non-covalent binding define the binding strength and 
therefore the selectivity of binding between different sequences (Tinti et al., 2013). Apart from 
its impact in schizophrenia, the ERBB sub family is known to be involved in, amongst other 
diseases, breast cancer and non-small cell lung cancer. The ERBB family is also critical for 
development, as exemplified by the heart deficiency observed in Erbb4 full knockout mice that 
are not vital. To date, many inhibitors that are selective for the sub family, such as lapatinib, 
have been developed (Davis et al., 2011). However, these inhibitors are not selective for a 
single family member causing side effects due to the wide range of physiological functions the 
different ERBBs exert in the body. Despite the importance of RTKs in various diseases, only 3% 
of marketed drugs target kinases (Santos et al., 2017). The development of a cell-based assay 
system that robustly and sensitively assesses the selectivity of RTKs may therefore contribute 
to the development of better medicines. 
The split TEV protein complementation Assay  
A protein fragment complementation assay (PCA) measures a protein-protein interaction 
(PPI), such as the recruitment of an adapter by a receptor or the dimerization of two receptors. 
PCAs are cell-based and genetically encoded, allowing the assessment of the interaction in its 
natural cellular environment. In a PCA, a reporter protein is split, and each part is covalently 
bound to the two proteins to be studied for an interaction. These interaction partners under 
study are termed bait and prey. Upon interaction of the two candidate proteins, the two 
moieties of the reporter protein functionally complement and thus regains activity. This 
activity is then translated into a stable and quantifiable read out. The first PCA experiment 
described used a split β-galactosidase (Rossi et al., 1997), followed by analogous approaches 
for GFP and luciferase (i.e. firefly, Renilla, Gaussia). This direct read out of split reporter activity 
was extended by fusing an artificial transcription factor to one moiety of the split reporter. 
Once this reporter complements, the transcription factor is cleaved off and migrates to the 
nucleus to induce a reporter gene of choice, such as a fluorescent protein or a luciferase. This 
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approach enables the signal indicating an occurred protein-protein interaction to be 
enhanced. The split ubiquitin and the split TEV (shown in figure T4) approach are the most 
renown examples of this approach (Wehr and Rossner, 2016). The split TEV technique has 
previously been used to monitor dynamic PPIs in both the cytosol and at the membrane in a 
robust, sensitive, and reproducible manner (Wehr et al., 2008, 2006). The split TEV system 
was used to monitor receptor tyrosine kinase activity in both the publications shown below. 
The split TEV method uses the functional complementation of two previously inactive 
fragments of the tobacco etch virus (TEV) protease (Wehr et al., 2006). The moieties have 
been termed NTEV and CTEV, and they are each fused to one of the interaction candidate 
proteins. The artificial transcription factor GAL4-VP16 (GV) is fused to NTEV via a TEV-specific 
cleavage site (tcs) in between. When the two candidate proteins interact, the TEV protease 
regains its activity, cleaving off GV at tcs, and therefore enabling GV to migrate to the nucleus. 
Here, GV binds to clustered upstream activating sequences (UAS). Upon binding of GV to UAS, 
the transcription of the firefly luciferase reporter gene is initiated. Independently, a Renilla 
luciferase is co-expressed under the control of the constitutive thymidine kinase promoter to 






Figure T4: Design of a versatile split TEV recruitment assay for receptor tyrosine kinases. 
Scheme of the split TEV recruitment assay for receptor tyrosine kinases (RTKs). RTKs are fused 
to an NTEV moiety along with a TEV protease cleavage site (tcs) and an artificial co-
transcriptional activator GAL4-VP16 (GV). Adapter proteins are fused to CTEV. Upon activation 
by a specific ligand (1), the RTK dimerizes, is cross-phosphorylated by the kinase domains at 
Tyr residues, providing docking sites for adapter proteins that bind to phosphorylated 
tyrosines (2). The ligand-induced interaction between RTK and adapter causes the NTEV and 
CTEV moieties to form a reconstituted TEV protease (2). Reconstituted TEV protease cleaves 
at tcs to release GV (3). Liberated GV migrates to the nucleus and initiates expression of firefly 





Schizophrenie ist eine psychische Erkrankung deren Symptome in Positivsymptome, 
Negativsymptome und kognitive Defizite aufgeteilt werden. Schizophrenie ist eine komplexe 
neurologische Entwicklungsstörung, bei der genetische Variation genauso wie 
Umwelteinflüsse beim Ausbruch im jugendlichen Alter eine Rolle spielen. Schizophrenie hat 
eine Erblichkeit von circa 80%, neueste GWAS Daten suggerieren hier eine hohe Polygenität. 
Störungen in der synchronisierten Inhibition von pyramidal Neuronen durch einen 
überaktiven NRG1-ERBB4 Signalweg führen zu einem Ungleichgewicht der Erregung und 
Hemmung (E/H-Balance), was mit den kognitiven Störungen in Verbindung gebracht werden 
kann. In diesem Sinne wäre zu erwarten, dass eine Hemmung der ERBB4 Aktivität die E/H-
Balance und damit die kognitiven Störungen wiederherstellen würde. 
Veröffentlichung 1: Deshalb haben wir die NIH Clinical Collection (727 FDA-zugelassene 
Medikamente) mithilfe der zellbasierten split TEV Technologie durchsucht und Spironolakton 
als ERBB4 Inhibitor identifiziert. In der ersten Veröffentlichung dieser kumulativen Thesis zeige 
ich, wie ich zur Validierung des Top-Hits Spironolakton beitragen konnte. Im Detail, habe ich 
die Inhibition der Dimerisierung der ERBB Rezeptorfamilie getestet (Figs 3E, F and EV 4A-J). 
Des weiteren konnte ich zeigen, dass gekürzte ERBB4 Rezeptoren, die keine intrazelluläre 
Domäne haben, nicht von Spironolakton inhibiert werden können (Fig. EV3 A-C). Zusätzlich 
war es mir, durch Western Blot Technologie, möglich zu zeigen, dass Spironolakton die 
Phosphorylierung von ERBB4 in kultivierten humanen Zellen reduziert (Fig. 4 A, B). Zusammen 
mit den Ergebnissen der elektrophysiologischen Experimenten und Maus Verhaltensstudien 
kann auf einen Einfluss auf die E/H-Balance durch ERBB4 Phosphorylierungsreduktion 
geschlossen werden. Dies führt zu einer Verbesserung der Schizophrenie relevanten 
Verhaltensphänotypen in Mäusen. 
Veröffentlichung 2. Spironolakton inhibiert allerdings nicht selektiv nur ERBB4 in der ERBB 
Familie (Wehr et al. 2017 Fig. 3F). Diese Selektivität ist schwer zu testen, wenn man 
verschiedene Bindungspartner miteinander vergleichen muss. Daher habe ich einen 
universalen RTK Adapter entwickelt, um die Selektivität von bekannten RTK Inhibitoren zu 
messen und Dosis-Wirkungs-Messungen in einem zellbasierten Hochdurchsatzscreen zu 
vergleichen. Ich konnte zeigen, dass ein künstlicher SH2 Domänen Adapter (SH2(GRB2)) das 
Signal-Rausch-Verhältnis verschiedener RTK Messungen verbessert, und so zu erhöhter 
Robustheit und Flexibilität der Messung beträgt. Zusammengefasst war es mir möglich die 
split TEV Technologie im Feld der RTK Aktivierungsmessung zu verbessern und für eine 
Applikation mit multiparametrischen parallelen Messungen zu öffnen. In dieser 
Veröffentlichung habe ich fast alle Experimente selbst durchgeführt und zu allen Abbildungen 
beigetragen. Den universellen Adapter konnten wir mithilfe eines RNA Barcodes zum 
simultanen Messen von  mehreren Assays mit Hilfe der Next-Generation-Sequenzierung 
nutzen. Zusätzlich reduziert dies die Anzahl an Proben und erhöht die Vergleichbarkeit der 




Zusammengefasst war der Inhalt meiner Arbeiten: in Veröffentlichung 1, dass ich zur 
pharmakologischen Validierung des NRG1-ERBB4 Signalwegs als ein Ziel für die bisher nicht 
therapierbaren kognitiven Defizite in der Schizophrenie beitragen konnte.  
In Veröffentlichung 2 habe ich eine umfassende Reihe von Assays entwickelt, die in der 





Schizophrenia is a severe mental disorder and its symptoms can be divided into positive and 
negative domains and treatment resistant cognitive deficits. Schizophrenia is a complex 
neurodevelopmental disease with both genetic variation and altered environmental cues 
playing a role in the outbreak around adolescence. Schizophrenia has a heritability of around 
80%, newest GWAS data suggests that it is highly polygenic. Disturbance of synchronous 
inhibition of pyramidal neurons by an hyperactivated NRG1-ERBB4 pathway causes excitation-
inhibition (E/I) imbalance and might be linked to cognitive deficits. In this vein, decreasing 
enhanced ERBB4 activity is expected to restore the E/I imbalance and cognitive deficits. 
Study 1: Therefore, we screened the NIH Clinical Collection (727 FDA-approved drugs) using 
the cell-based split TEV technology and identified spironolactone to inhibit ERBB4 activation. 
In the first publication of this cumulative thesis I show how I contributed to the validation this 
top hit spironolactone. Specifically, I generated data sets testing the inhibition to other dimers 
formed by the ERBB family (Figs 3E, F and EV 4A-J). Further, I was able to show that truncated 
ERBB4 receptors that lack the intracellular domain, cannot be inhibited by spironolactone (Fig. 
EV3 A-C). In addition, using Western blotting, I was able to confirm that spironolactone 
reduces phosphorylation levels of ERBB4 in human cultured cells (Fig. 4 A, B). Together with 
the findings in electrophysiology and behavioral mouse studies, we can conclude that 
spironolactone alters the E/I balance by decreasing ERBB4 phosphorylation, leading to an 
improvement of schizophrenia-relevant behavioral phenotypes in mice. 
Study 2. However, spironolactone is not selective for ERBB4 amongst the ERBB family (Wehr 
et al. 2017 Fig. 3F). This selectivity is hard to address technically when using various binding 
partners for dimerization and different adapters within the ERBB family. Hence, in the second 
study shown in this thesis, I designed a universal RTK adapter to measure and compare the 
selectivity of known RTK inhibitors in dose–response profiling and cell-based high-throughput 
screening (HTS) assays. I was able to show that the synthetic clustered SH2(GRB2) domain 
adapter increased signal-to-noise ratios of various RTK assays and thus enhanced the 
robustness and flexibility of the assays in general. In summary, I was able to establish an 
improved split TEV recruitment assay to monitor RTK activities, with the potential for its 
application of multiplexed assays that are run in parallel. In this publication, I performed nearly 
all experiments myself and contributed to all figures. This universal adapter also enables us to 
multiplex RTK measurements. Using an RNA barcode reporter, we can measure various assays 
simultaneously using next-generation sequencing as final readout. In addition, the number of 
samples needed is decreased and comparability among RTK dose-response assays is 
increased, an important step towards HTS compound profiling. 
The general impact of my studies are: (i) I could contribute to the pharmacological validation 
of the NRG1-ERBB4 pathway as a target of the so far treatment-resistant cognitive deficits for 
schizophrenia; (ii) I developed a comprehensive set of assays that may help to develop 
compounds with enhanced selectivity for ERBB4 in the future.  
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Abstract
Enhanced NRG1-ERBB4 signaling is a risk pathway in schizophre-
nia, and corresponding mouse models display several endopheno-
types of the disease. Nonetheless, pathway-directed treatment
strategies with clinically applicable compounds have not been
identified. Here, we applied a cell-based assay using the split TEV
technology to screen a library of clinically applicable compounds
to identify modulators of NRG1-ERBB4 signaling for repurposing.
We recovered spironolactone, known as antagonist of corticos-
teroids, as an inhibitor of the ERBB4 receptor and tested it in
pharmacological and biochemical assays to assess secondary
compound actions. Transgenic mice overexpressing Nrg1 type III
display cortical Erbb4 hyperphosphorylation, a condition observed
in postmortem brains from schizophrenia patients. Spironolac-
tone treatment reverted hyperphosphorylation of activated Erbb4
in these mice. In behavioral tests, spironolactone treatment of
Nrg1 type III transgenic mice ameliorated schizophrenia-relevant
behavioral endophenotypes, such as reduced sensorimotor gating,
hyperactivity, and impaired working memory. Moreover, spirono-
lactone increases spontaneous inhibitory postsynaptic currents in
cortical slices supporting an ERBB4-mediated mode-of-action.
Our findings suggest that spironolactone, a clinically safe drug,
provides an opportunity for new treatment options for
schizophrenia.
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split TEV assay
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Introduction
Schizophrenia (SZ) is as severely debilitating neuropsychiatric disor-
der characterized by positive symptoms, that is, hallucinations and
delusions, negative symptoms, that is, lack of motivation, and
cognitive symptoms (Insel, 2010). Positive symptoms can frequently
be ameliorated by treatment with dopamine receptor antagonists,
but efficient treatment options for negative and cognitive symptoms
are not available (Goff et al, 2011). Thus, there is a strong clinical
need to develop and explore more target-directed therapies for SZ
(Nestler & Hyman, 2010). Repurposing of existing drugs principally
offers a fast track to the clinic and has been demanded for SZ (Insel,
2012; Lencz & Malhotra, 2015), also because many pharma compa-
nies withdrew from research on severe mental disorders (Margraf &
Schneider, 2016). Genetic association studies have identified NRG1
and its cognate receptor ERBB4 as SZ risk genes, and altered NRG-
ERBB4 signaling has been associated with positive, negative, and
cognitive symptoms (Stefansson et al, 2002; Harrison & Law, 2006;
Li et al, 2006; Nicodemus et al, 2006). Several postmortem studies
revealed increased expression of NRG1 in SZ patients (Hashimoto
et al, 2004; Law et al, 2006; Weickert et al, 2012). Elevated expres-
sion of the ERBB4-JM-a-CYT-1 variant carrying a PI3K-recruitment
domain has also been detected in SZ (Silberberg et al, 2006;
Law et al, 2007, 2012). Moreover, ERBB4 was found to be
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hyperphosphorylated in postmortem brains from SZ patients (Hahn
et al, 2006), suggesting that NRG1-ERBB4 hyperstimulation might
represent a component of SZ pathophysiology.
In agreement, transgenic mice with increased Nrg1 expression
display SZ-relevant behavioral deficits, including hyperactivity,
impaired sensorimotor gating, decreased social interaction, and
reduced cognitive functions (Deakin et al, 2009, 2012; Kato et al,
2010). In particular, transgenic mice with neuronal overexpression of
the membrane-bound cysteine-rich-domain (CRD) type III isoform of
Nrg1 (Nrg1-tg) display chronic ErbB4 hyperphosphorylation in the
cortex, which is associated with a broad spectrum of SZ-relevant
endophenotypes, including dysbalanced excitatory and inhibitory
neurotransmission, altered spine growth, and impaired sensorimotor
gating (Agarwal et al, 2014). Moreover, it has been shown recently
that endophenotypes associated with elevated Nrg1 expression are
reversible in adult animals, which strongly supports the assumption
that the NRG1/ERBB4 signaling system provides a valid target for
pharmacological interventions (Yin et al, 2013; Luo et al, 2014). It thus
appears plausible that compounds, which can re-balance the activity of
the NRG1-ERBB4 signaling pathway, could represent candidates for
the therapeutic treatment of schizophrenia beyond positive symptoms.
In this study, we have first developed a co-culture assay system
compatible with high-throughput-screening (HTS) utilizing the split
TEV technology (Wehr et al, 2006, 2008). We then used this assay
to screen a library of clinically approved drugs in a repurposing
approach to uncover new potential target specificities (Wang &
Zhang, 2013), which resulted in the identification and validation of
spironolactone as an inhibitor of ERBB4. Finally, we can show that
spironolactone decreases phosphorylation levels of ERBB4 in vitro
and in vivo and leads to an altered balance of excitation/inhibition
of cortical projection neurons. Chronic spironolactone treatment
ameliorates hyperactivity and reverses sensorimotor gating and
working memory deficits in Nrg1-tg mice. Thus, spironolactone alle-
viates novel aspects of SZ-relevant symptoms in this mouse model
of increased NRG1-ERBB4 signaling.
Results
A split TEV-based co-culture assay to screen for modulators of
NRG1-ERBB4 signaling
Screening for modulators of NRG1-ERBB4 signaling in cell culture
requires an adequate setup reflecting endogenous signaling mecha-
nisms. According to a current model, NRG1 ligands reside in presy-
naptic terminals of principle pyramidal neurons, whereas ERBB4
receptors are mainly expressed at the postsynaptic density of
dendrites in inhibitory interneurons (Rico & Marı́n, 2011). Based on
this ligand-receptor configuration, NRG1 mediates juxtacrine and
paracrine signaling to ERBB4. We established a cellular HTS-compa-
tible co-culture assay, in which NRG1 was expressed in the signal-
sending cell population A, whereas ERBB4 was expressed in the
signal-receiving cell population B (Fig 1A). Initially, we used the full-
length NRG1 type I b1a isoform that undergoes proteolytic cleavage
resulting in the release of the extracellular domain, which contains
the biologically active EGF-like domain (EGFld), into the extracellular
space (Hu et al, 2006; Willem et al, 2006). Therefore, NRG1 type I
b1a can elicit juxtacrine (non-cleaved form) and paracrine (cleaved
form) stimuli. To screen for approved small compounds that could
modulate NRG1-ERBB4 signaling, we combined this co-culture assay
with the split TEV protein–protein interaction technique to monitor
ERBB4 activation through induced PI3K adaptor recruitment by the
human ERBB4-JMa-Cyt1 variant (Fig 1A).
The functionality and robustness of the co-culture assay was
investigated by co-plating increasing numbers of PC12 cells carrying
a stably integrated mouse Nrg1 type I b1a expression cassette (Nrg1
cells, Fig EV1A for stable Nrg1 expression) with ERBB4-PIK3R1-
expressing PC12 cells (split TEV assay cells). Co-culture conditions
were verified using two PC12 cell populations expressing either
EYFP or ECFP (Fig EV1B). A dose–response analysis showed that
the assay reached a plateau of activation when 10,000 Nrg1-
expressing cells were co-plated with 40,000 split TEV assay cells,
with half-maximal activation at 5,000 cells (Fig 1B). Calculation of
the Z’ factor, a measure of HTS applicability and quality (Zhang
et al, 1999), resulted in a value of 0.5 indicating a large separation
band at screening conditions. Importantly, addition of the soluble
EGFld resulted in a twofold increase of ERBB4 activation compared
with Nrg1 cells alone, implying that ERBB4 activation in the co-
culture assay can be decreased and increased by potential NRG1-
ERBB4 inhibitors and activators, respectively (Fig 1C). In addition,
dose–response assays using ERBB4-PIK3R1 split TEV assay cells
only and soluble EGFld as stimulus (single-culture assay) showed
stable and reproducible dose–responses that also qualified for HTS,
with Z’ factors between 0.56 and 0.68 for three independent assays
(Fig EV1C). The specificity of the NRG1-ERBB4 co-culture assay
was validated in dose–response assays using established ERBB4
inhibitors, such as lapatinib (IC50 value at 2.61 lM, co-culture
assay, Fig 1D; 0.45 lM, single-culture assay, Fig EV1D) and CI-1033
(IC50 value at 0.01 lM, co-culture assay, Fig EV1E; 0.004 lM,
single-culture assay, Fig EV1F). Taken together, these data indicate
that the split TEV-based co-culture assay provides a robust platform
to screen for modulators of NRG1-ERBB4 signaling.
Screening the NIH clinical compound collection recovers
spironolactone as ERBB4 receptor antagonist
We used the split TEV-based NRG1-ERBB4-PIK3R1 co-culture assay
to screen two sets of the NIH Clinical Collection (NIH-NCC) contain-
ing 727 FDA-approved drugs in total (Fig 2A). From this screen, we
selected a primary hit list of candidates that were at least three stan-
dard deviations away from the mean (Fig 2B for NIH-NCC set 1;
Fig EV2A for NIH-NCC set 2; Dataset EV1). These candidates were
then subjected to individual re-screening to eliminate off-target
effects, such as toxicity and interference with assay tools, and 18
substances met these criteria and were selected for the final hit list
(Appendix Fig S1 for a flowchart of all screening and validation
steps; see Appendix Table S1 for final hit list). Spironolactone, a
mineralocorticoid receptor (MR) antagonist formerly used as a
diuretic and to treat high blood pressure (Gaddam et al, 2010), was
recovered as top antagonist candidate (Fig 2B). In a dose–response
co-culture assay using Nrg1 type I b1a, spironolactone displayed an
IC50 value of 1.0 lM, and marginal toxic effects at higher concentra-
tions, as indicated by reduced Renilla luciferase readings (Fig 2C).
ERBB4-specific effects were confirmed by dose–response control
assays, which showed absence of spironolactone effects on assay
components (Fig EV2B and C).
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Importantly, spironolactone also inhibited ERBB4 activity (IC50
value of 1.1 lM) in a co-culture assay using the membrane-bound CRD
containing type III isoform of Nrg1, the major NRG1 isoform in the
brain, which is implicated in juxtacrine signaling (Fig 2D). Thus,
spironolactone modulates ERBB4 activity downstream from both para-
crine and juxtacrine NRG1 signaling. Further, spironolactone acts at a
proximal step of ERBB4 receptor activation upstream of tyrosine phos-
phorylation and adapter recruitment as ERBB4 dimerization stimulated
by EGFld was efficiently inhibited (IC50 value of 1.1 lM) in a single-
culture assay (Fig 2E). Finally, we used an ERBB4 variant that lacks the
intracellular domain, and thus is signaling incompetent, but expresses
at the cell cortex and dimerizes upon EGFld stimulation (Fig EV3A and
B). Notably, spironolactone inhibits dimerization of full-length ERBB4,
but not of C-terminally truncated ERBB4 (Fig EV3C).
Spironolactone but not its metabolic products antagonizes the
ERBB4/PIK3R1 assay
Spironolactone also inhibited ERBB4 signaling activity in an ERBB4-
PIK3R1 single-culture assay, albeit with a slightly increased IC50



































































Figure 1. A co-culture assay based on the split TEV technique for monitoring NRG1-ERBB4 signaling activity.
A The ERBB4-PIK3R1 split TEV assay monitors NRG1-ERBB4 signaling in PC12 cells. The Nrg1 ligand (green) is stably expressed in the signal-sending cell population A.
The signal-receiving cell population B (or split TEV assay cells) is transfected with plasmids encoding the assay components ERBB4 (red) fused to NTEV-tevS-GV
(ERBB4-NTEV-tevS-GV), the adapter molecule PIK3R1 (purple, the regulatory subunit alpha of the PI3K) fused to CTEV (PIK3R1-CTEV), and a UAS-driven firefly
luciferase reporter (Fluc). Upon Nrg1 binding to the extracellular domain of ERBB4 (1), ERBB4-NTEV-tevS-GV dimerizes and cross-phosphorylates itself (2). PIK3R1-
CTEV binds to the phosphorylated ERBB4 receptor leading to the functional reconstitution of TEV protease activity and the concomitant release of the artificial co-
transcriptional activator Gal4-VP16 (GV) through proteolytic cleavage at a TEV protease cleavage site (tevS) (3). In turn, released GV translocates to the nucleus and
binds to UAS sequences (open box) to activate the transcription of a firefly reporter gene (4).
B Dose–response assay using increasing numbers of Nrg1 type I b1a-expressing PC12 cells. For each 96-well, 40,000 split TEV assay cells were co-plated with increasing
numbers of Nrg1-expressing cells and incubated for 24 h. Half-maximal activation is reached at 5,000 Nrg1-expressing cells. The Z’ factor is 0.5 indicating a large
separation band for this assay.
C Adding 10 ng/ml EGFld resulted in a twofold activation. Per 96-well, 40,000 split TEV assay cells were co-plated with empty PC12 cells (no Nrg1 expression), 10,000
Nrg1-expressing cells, and 10,000 Nrg1-expressing cells plus 10 ng/ml EGFld. Arrows indicate measuring window of activation (blue arrow) and inhibition (red arrow)
relative to baseline activity.
D Lapatinib antagonizes ERBB4-PIK3R1 signaling in a dose-dependent manner. Per 96-well, 40,000 split TEV assay cells were incubated with increasing amounts of
lapatinib, followed by co-plating 10,000 Nrg1 type I b1a-expressing cells. The inset depicts the IC50 value in lM.
Data information: After compound/stimulus addition, each assay was incubated for 24 h. RLU, relative luciferase units; Fluc, firefly luciferase activity (black line); Rluc,
Renilla luciferase activity (gray line); n = 6; data are shown as mean, and error bars represent SEM.
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Figure 2. Spironolactone is the primary candidate recovered from the co-culture screen.
A Flow chart of the compound screen. PC12 cells (population A) were transfected in solution with the split TEV assay plasmids ERBB4-NTEV-tevS-GV and PIK3R1-
CTEV and incubated for 2 h before seeded onto 96-well plates. Population A cells were allowed to express the plasmids for 24 h. Compounds were added in a
concentration of 10 lM, followed by seeding the Nrg1-expressing PC12 cells (population B) half an hour later. After 24 h of compound incubation, cells were lysed
and subjected to a dual luciferase assay. The screening data were analyzed using the cellHTS2 package in R Bioconductor.
B Graphic visualization of the primary screen data of the NIH-NCC library set 1. All counts (320 compounds and 64 controls) from the Nrg1-ERBB4-PIK3R1 split TEV
compound screen were plotted against the Z-score using the Mondrian program, with pathway activators displaying high values and inhibitors low values. For the
secondary analysis, we selected all candidates that were at least three standard deviations away from the mean. EGFld-positive and lapatinib/CI-1033-negative
controls are shown in red.
C, D Spironolactone antagonizes Nrg1-ERBB4-PIK3R1 signaling. In dose–response assays using ERBB4-NTEV-tevS-GV and PIK3R1-CTEV plasmids transfected into PC12
cells, spironolactone was administered at increasing concentrations before seeding (C) Nrg1 type I- or (D) Nrg1 type III-expressing PC12 cells.
E Spironolactone inhibits ERBB4 receptor dimerization. Dose-dependent dimerization of the ERBB4 receptor was analyzed using a split TEV assay encompassing
ERBB4-NTEV-tevS-GV and ERBB4-CTEV plasmids transfected into PC12 cells. 10 ng/ml EGFld was applied as Nrg1 stimulus.
Data information: Fluc, firefly luciferase activity (black lines); Rluc, Renilla luciferase activity (gray lines, indicating toxicity levels); n = 6; data are shown as mean, and
error bars represent SEM. The insets depict IC50 values in lM.
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value of 2.8 lM (Fig 3A). We used the assay to identify molecular
structures in spironolactone (Fig 3A) required for the inhibition of
ERBB receptor activation in this assay and examined structurally
highly related compounds, such as the metabolites canrenone
(Fig 3B) and 7a-thiomethyl-spironolactone (Fig 3C) as well as the
second-generation MR antagonist eplerenone (Fig 3D). Canrenone
lacks the thio-ketone group attached to the sterol core structure,
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Figure 3. Multilevel profiling approach of spironolactone treatment assessing target specificities and adapter recruitment.
A Spironolactone, molecular structure shown on the left, inhibits ERBB4/PIK3R1 split TEV assay activity (black line), with an IC50 value of 2.76 lM.
B–D The spironolactone metabolites (B) canrenone and (C) 7a-thiomethyl-spironolactone as well as the second-generation drug (D) eplerenone do not attenuate the
ERBB4/PIK3R1 assay activity (black lines). Note that only spironolactone bears a thio-ketone group attached to the sterol core structure. All ERBB4/PIK3R1 assays
were run in a single-culture assay mode using 10 ng/ml EGFld as functional Nrg1 stimulus, and ERBB4-NTEV-tevS-GV and PIK3R1-CTEV plasmids were transfected
into PC12 cells (indicated by icon).
E Schematic representation of the most critical ERBB dimers tested in spironolactone dose–response assays using the split TEV protein–protein interaction detection
technique. Note that not all possible combinations are depicted.
F Heat map showing the IC50 values obtained from individual ERBB dimerization split TEV assays. All single dose–response assays can be found in Fig EV4; the
combination ERBB4-ERBB4 is shown in Fig 2E.
Data information: Fluc, firefly luciferase activity (black lines, reporting ERBB4-PIK3R1 assay activity); Rluc, Renilla luciferase activity (gray lines, assessing viability); n = 6;
data are shown as mean, and error bars represent SEM. The insets depict IC50 values in lM.
EMBO Molecular Medicine Vol 9 | No 10 | 2017 ª 2017 The Authors
EMBO Molecular Medicine Spironolactone inhibits NRG1-ERBB4 signaling Michael C Wehr et al
1452
In eplerenone, the thio-ketone group is replaced by an acidic group,
in addition to a minor modification at the sterol core structure.
None of these compounds showed an inhibitory effect in the
ERBB4-PIK3R1 single-culture assay (Fig 3B–D), suggesting that the
thio-ketone group specific for spironolactone plays a role for its
inhibitory function in this assay.
Spironolactone preferentially inhibits dimers containing ERBB4
Target specificity is a crucial aspect for the evaluation of pharmaco-
logical active compounds (Feng et al, 2009). As ERBB4 is a member
of the ERBB family, we determined spironolactone’s antagonistic
effects on dimer formation of other ERBB receptors (Fig 3E). As
indicated by IC50 values obtained from dose–response assays
(Figs 3F and EV4A–I), spironolactone preferentially inhibits forma-
tion of ERBB4 homodimers (at 1.75 lM). Spironolactone antago-
nizes also other ERBB combinations, albeit with less efficacy, and
efficiently inhibits EGFR homodimer formation when stimulated by
EGF (at 1.74 lM) (Figs 3F and EV4J). Collectively, these data
suggest that spironolactone acts as a pan-ERBB family inhibitor,
which preferentially inhibits dimer formation involving EGFR or
ERBB4. In adult cortical tissues of mice, however, EGFR is not
detectably expressed (Appendix Fig S2), suggesting that ERBB4 is
the major target of the ERBB family for spironolactone in the brain.
Spironolactone reverts ERBB4 hyperphosphorylation
Dose–response assays indicated that spironolactone reduces the
phosphorylation-dependent recruitment of PIK3R1 by activated
ERBB4 (Figs 2C and 3A), prompting us to examine the phosphoryla-
tion levels reverted by spironolactone biochemically. EGFld treat-
ment of human T-47D cells that endogenously express ERBB4
induced hyperphosphorylation at Tyr1056 and Tyr1284 of ERBB4.
Addition of lapatinib completely reverted Tyr1056 and Tyr1284
phosphorylation, whereas treatment with spironolactone reduced
phosphorylation to intermediate levels (Fig 4A and B) Likewise,
spironolactone antagonized EGFld-mediated hyperphosphorylation
of transfected human ERBB4 in PC12 cells that were used in the
screen (Fig EV3D). To translate our findings into a potential thera-
peutic rationale for SZ, we utilized a transgenic mouse model, in
which Nrg1 type III is overexpressed under the control of the
neuronal Thy1.2 promoter (referred to as Nrg1-tg) and causes hyper-
phosphorylation of ERBB4 receptors in the prefrontal cortex
(Velanac et al, 2012). We tested whether phospho-ERBB4 levels
were also regulated by chronic spironolactone treatment in Nrg1-tg
mice and injected the drug for 21 consecutive days before sacrificing
the mice for biochemical analysis (Fig 4C). In lysates from mouse
prefrontal cortex, phospho-Erbb4 levels were efficiently visualized
using the p-ERBB4-Y1284 antibody (Fig 4D and E). Notably, addi-
tion of spironolactone resulted in a robust reduction of NRG1-
induced ERBB4 hyperphosphorylation. Downstream signaling
effects, as assessed by pERK and pAKT, were neither modulated by
Nrg1 overexpression, nor by spironolactone treatment. Next, we
tested whether LIM kinase 1 (LIMK1) displays regulated phosphory-
lation levels upon spironolactone treatment. LIMK1 is a non-
receptor protein serine/threonine kinase implicated in cytoskeleton
dynamics and the regulation of synaptic spine morphology and
function (Meng et al, 2002, 2004) and has been associated with
NRG1 signaling (Yin et al, 2013). Notably, phospho-Limk1 levels
were slightly upregulated in wt and markedly upregulated in
spironolactone-treated Nrg1-tg mice, suggesting that LIMK1 activity
integrates, at least in part, spironolactone’s inhibitory effect (Fig 4D
and E). Taken together, these results indicate that spironolactone
serves as an inhibitor of NRG1-mediated ERBB4 signaling.
Since NRG1-ERBB4 signaling has been shown to modulate inhibi-
tory neurotransmission (Yin et al, 2013; Agarwal et al, 2014; Mei &
Nave, 2014), we tested the impact of spironolactone treatment on
synaptic transmission in acute slices prepared from prefrontal
cortex. When we measured spontaneous inhibitory postsynaptic
currents (sIPSCs) at layer II/III pyramidal neurons, canrenone
(10 lM) showed no significant effect on sIPSC frequencies and
amplitudes (Fig 4F). In contrast, administration of spironolactone
(10 lM) caused an increase of sIPSC frequency (n = 12; P < 0.05)
and amplitude (n = 12, P < 0.05) shortly after bath application
(Fig 4G). Next, evoked IPSCs were measured in pyramidal neurons
in layer II/III of prelimbic cortex after stimulating in layer I. To
distinguish between MR and ERBB4-mediated effects by spironolac-
tone, these experiments were performed in the presence of canre-
none (10 lM), which is a more potent MR antagonist relative to
spironolactone. Under these conditions, spironolactone (5 lM)
significantly increased the eIPSC amplitude (Fig 4H), a finding also
increased by the pan-ERBB family inhibitor compound lapatinib as
control (5 lM) (Fig 4I). Together, these findings are consistent with
the hypothesis that spironolactone modulates GABAergic neuro-
transmission via ERBB4.
Chronic spironolactone treatment ameliorates SZ-relevant
behavioral endophenotypes in Nrg1-tg mice
Nrg1-tg mice exhibit SZ-relevant behavioral abnormalities, including
deficits in prepulse inhibition (PPI) (Agarwal et al, 2014), an opera-
tional measure of sensorimotor gating. In a pilot experiment, we
performed a two-arm study, in which Nrg1-tg and wt mice were
tested for PPI before and after chronic spironolactone treatment as
above (Fig EV5A). Before treatment, Nrg1-tg mice displayed PPI
deficits (Fig EV5B), in line with our previous findings (Agarwal
et al, 2014). Spironolactone treatment significantly improved PPI in
Nrg1-tg mice (Fig EV5C), but had no effect in wt controls, suggest-
ing that spironolactone modulates behavioral deficits of enhanced
NRG1-ERBB4 signaling (Fig EV5D).
Based on these results, we performed a four-arm study, in which
an independent cohort of Nrg1-tg and wt mice was tested following
spironolactone or vehicle treatment (Fig 5A). In this study, we
assessed a battery of behavioral domains with relevance for SZ,
such as motor activity, curiosity, light–dark preference, working
memory, motivation, PPI, fear memory, and pain sensitivity.
Vehicle-treated Nrg1-tg mice covered longer distances in the
open-field arena than vehicle-treated wt controls (Fig 5B and C).
This locomotor hyperactivity, however, was reverted by spironolac-
tone (Fig 5B and D). Further, Nrg1-tg mice showed, increased anxi-
ety, paralleled by higher frequency of defecation and urination
during the open-field test (Fig EV5E–G), supporting previous obser-
vations (Agarwal et al, 2014). When testing for light–dark prefer-
ence, spironolactone-treated Nrg1-tg spent more time in the light
compartment. This suggests an anxiolytic rather than a sedative
effect of spironolactone (Fig 5E), as Nrg1-tg animals and wt controls
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displayed a similar transition activity in the light–dark test
(Fig EV5H). In contrast, Nrg1-tg mice showed an increased activity
in the tail suspension test (Fig EV5I). Working memory was
assessed in the Y-maze test. Nrg1-tg mice performed significantly
less alterations than wt controls, suggesting an impaired working
memory performance in transgenics (Fig 5F). Notably, spironolac-
tone treatment rescued these deficits (Fig 5F), without influencing
the activity in the Y-maze (Fig EV5J). However, the number of
choices was higher in transgenics, supporting their hyperactivity
phenotype observed in the open-field test (Fig 5B and C).
In the contextual fear memory test, spironolactone-treated
Nrg1-tg mice displayed a non-significant reduction in freezing
(Fig EV5K), which was paralleled by significantly decreased
levels of pain sensitivity as assessed in the hot plate test
(Fig EV5L). Cue memory testing revealed neither genotype nor
treatment-dependent alterations (Fig EV5K). Moreover, spirono-
lactone treatment significantly enhanced PPI in Nrg1-tg (Fig 5G),
but not in wt mice (Fig EV5M), replicating the data obtained from
the pilot experiment (Fig EV5D).
As Nrg1 is a critical regulator for brain development, we aimed
to exclude age-related consequences on the behavioral effects
observed using a covariate analysis, which links age with test
performance. To do this, we grouped mice into juvenile
(8–11 weeks) and adult (12–16 weeks) categories, and ANCOVA
with the covariate age did not reveal an effect on the genotype-
dependent treatment response (Appendix Fig S3).
Taken together, chronic spironolactone treatment alleviates
hyperactivity, PPI and working memory deficits in Nrg1-tg mice,
findings that are paralleled by a reduction in Erbb4 hyperphosphory-
lation levels in these mice.
Discussion
To obtain repurposed drugs for schizophrenia, we have developed a
co-culture assay system mimicking several proximal aspects of
NRG1-ERBB4 signaling (Citri & Yarden, 2006; Mei & Xiong, 2008). Its
successful application in a repurposing screen with clinical
substances resulted in the identification of the MR antagonist
spironolactone as a potent ERBB4 inhibitor. The efficacy of spirono-
lactone as novel inhibitor of NRG1-ERBB4 signaling was validated in
heterologous cells with an endogenous expression of human ERBB4
and in vivo using transgenic mice, which model NRG1 overexpres-
sion and ERBB4 hyperphosphorylation linked to several endopheno-
types with relevance for SZ (Agarwal et al, 2014). We thus provide a
pharmacological proof-of-principle for targeting NRG1-ERBB4 signal-
ing in the context of SZ and exploited the opportunity to repurpose a
clinical compound, a strategy that was strongly demanded in the last
years for mental diseases (Insel, 2012). In addition, a recent study
suggested to fast track all SZ susceptibility genes, which encode
potential targets for approved drugs, for repurposing (Lencz &
Malhotra, 2015). Therefore, our multilevel approach targeting NRG1-
ERBB4 signaling that identified a hidden mode-of-action of spirono-
lactone antagonizing ERBB4 activity strongly supports this approach.
As spironolactone is a clinically safe and available substance, it
immediately qualifies for therapeutic intervention trials. Finally, the
co-culture assay is qualified for high-throughput conditions under
industry quality standards and will allow the exploratory screen of
large exploratory compound libraries.
Spironolactone inhibited the association between ERBB4 and
PIK3R1 in the split TEV-based co-culture assay, with an IC50 value
at approximately 1 lM. Our data suggest that spironolactone also
targets other ERBB family members, however, with a preference for
ERBB4. Our biochemical analysis suggests that spironolactone
shows an intermediate efficacy of ERBB4 inhibition. Notably, fine
tuning of excitation and inhibition between excitatory projection
neurons expressing NRG1 and inhibitory parvalbumin-positive
interneurons expressing ERBB4 is thought to be a critical determi-
nant of endophenotypes observed in gain- and loss-of-function
mouse models (Chen et al, 2010; Yin et al, 2013; Agarwal et al,
2014). Therefore, moderate changes in NRG1/ERBB4 activity may
be desired to achieve rebalanced signaling levels under pathological
◀ Figure 4. Spironolactone antagonizes ERBB4 phosphorylation both in in vitro and in vivo.A Spironolactone reduces ERBB4 levels. T-47D cells were stimulated with 10 ng/ml EGFld, 10 lM lapatinib and 10 lM spironolactone for 5 min as indicated. Cell
lysates were probed for ERBB4 phosphorylation levels at Tyr1056 and Tyr1284.
B Quantification of band intensities for phospho-ERBB4 levels (n = 4 per condition) shown in (A) using ImageJ. Phosphorylation levels are normalized to protein levels
of ERBB4. Data are shown as mean, and error bars represent SD; t-test, with *P = 0.0356 for p-ERBB4 (Y1056), and **P = 0.0079 for p-ERBB4 (Y1284).
C Experimental design for Western blot analysis shown in (D) and (E). Nrg1-tg and wt animals were treated daily with spironolactone (50 mg/kg, s.c.) or vehicle (n = 2
per genotype and per treatment) for 21 days.
D Spironolactone reduces phospho-Erbb4 levels in Nrg1-tg mice. Mice were treated with spironolactone for 21 days and sacrificed for Western blot analysis. Lysates
were probed with indicated antibodies.
E Quantification of band intensities for phospho-Erbb4 and phospho-Limk1 levels (n = 2 per condition) shown in (D) using ImageJ. Phosphorylation levels are normalized
to protein levels of Erbb4 and Limk1. Data are shown as mean, and error bars represent SD; t-test, with *P = 0.0330 for p-Erbb4, and *P = 0.0201 for p-Limk1.
F Canrenone (applied as 10 lM) showed no effects on frequencies and amplitudes of sIPSCs in pyramidal neurons of the prefrontal cortex (PFC). Representative traces
of sIPSCs (upper) and a histogram of mean sIPSC (lower) are shown for both before and after addition of canrenone.
G Spironolactone (applied as 10 lM) significantly increases frequencies (n = 12; *P = 0.0454) and amplitudes (n = 12, *P = 0.0478) of sIPSCs in pyramidal neurons of
PFC. Representative traces of sIPSCs (upper) and a histogram of mean sIPSC (lower) are shown for both before and after addition of spironolactone.
H Spironolactone increases amplitudes of evoked IPSCs in pyramidal neurons of PFC (n = 15, *P = 0.0286). Spironolactone (5 lM) was applied in the presence of
canrenone (10 lM).
I Lapatinib increases amplitudes of evoked IPSCs in pyramidal neurons of PFC (n = 15, *P = 0.0124). Lapatinib was applied at 5 lM. Arrow indicates an evoked IPSC
stimulus.
Data information: For (H, I), sample recording (upper) and a histogram of averaged eIPSC (lower) is shown for both before and after drug application. For (F–I), the
numbers displayed inside the histogram bars indicate the number of recorded slices/number of animals. Data are shown as mean, and error bars represent SD (for B, E)
and SEM (for F–I); paired t-test, with *P ≤ 0.05; Spiro, spironolactone; Canre, canrenone; Lap, lapatinib.
Source data are available online for this figure.
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conditions. We found that the chronic administration of spironolac-
tone to Nrg1-tg mice reverted Erbb4 hyperphosphorylation and
largely rescued hyperactivity (considered as a surrogate marker for
positive symptoms in SZ), PPI deficits and working memory impair-
ments. Importantly, behavior in wild-type mice remained largely
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Figure 5. Chronic spironolactone treatment ameliorates deficits of behavioral endophenotypes in Nrg1-tg mice.
A Experimental design. Nrg1-tg and wt animals were treated daily with spironolactone (50 mg/kg, s.c.) or vehicle (n = 12 per genotype and per treatment) for
3 weeks, followed by behavioral phenotyping using the tests as indicated. Spironolactone or vehicle treatment was continued throughout the phenotyping
phase.
B Nrg1-tg mice travelled longer distances in the open-field arena (effect of genotype F1,44 = 10.53; P = 0.0022; two-way ANOVA). Bonferroni post hoc analysis revealed a
significant genotype-dependent difference between vehicle-treated groups (**P = 0.0044) but not in spironolactone-treated groups (P = 0.3783). Genotype differences
were abolished upon spironolactone treatment.
C When vehicle-treated animals were analyzed in 1-min intervals, transgenic mice showed an increased activity throughout the entire test (effect of genotype F1,22 = 9.27;
P = 0.0060; two-way ANOVA), most prominent in intervals 2, 7, and 8 (*P = 0.0427, *P = 0.0385, and ***P = 0.000036, respectively, Bonferroni post hoc test).
D There was no significant difference between the genotypes when treated with spironolactone (effect of genotype F1,22 = 2.19; P = 0.1535; two-way ANOVA). However,
the interaction of genotype and treatment was significant (F9,198 = 1.94; P = 0.0481; two-way ANOVA).
E Nrg1-tg mice treated with spironolactone spent more time in the light compartment during the light–dark test (interaction gene × treatment F1,41 = 4.90;
P = 0.0324; two-way ANOVA, and *P = 0.0219, Bonferroni post hoc test).
F In the Y-maze test, transgenic mice performed less alterations (effect of genotype F1,44 = 11.50; P = 0.0015; two-way ANOVA). The Bonferroni test confirmed this
phenotype in vehicle-treated groups (**P = 0.0011), but not in spironolactone-treated animals (P = 0.5950). Spironolactone treatment had a significant effect on the
number of alterations (F1,44 = 4.12; P = 0.0484; two-way ANOVA).
G Spironolactone treatment significantly enhanced PPI in Nrg1-tg mice (effect of treatment F1,21 = 5.07; *P = 0.0325; two-way repeated-measures ANOVA).
Data information: Data are shown as mean, and error bars represent SEM. Spiro, spironolactone; Veh, vehicle. n = 12 per genotype and treatment with an exception of
(E) (Nrg1-tg vehicle, n = 11; Nrg1-tg Spiro, n = 10; wt vehicle, n = 12; wt Spiro, n = 12) and (G) (Nrg1-tg vehicle, n = 11; Nrg1-tg Spiro, n = 12.
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not canrenone, enhanced inhibitory neurotransmission when
applied acutely to cortical slices of wild-type mice, suggesting an
ERBB4-mediated mechanism. Likewise, the ERBB4 kinase inhibitor
lapatinib caused similarly increased IPSCs within the same experi-
mental model. Increased amplitudes of mIPSCs have also been
observed in conditional Nrg1 loss-of-function mutants, most likely
as a consequence of reduced activity of ERBB4 in inhibitory neurons
(Agarwal et al, 2014). In conditional ERBB4 mutants, however,
mIPSC frequencies were reduced in the hippocampus (Fazzari et al,
2010). A recent study reports that NRG2, a close relative of NRG1, is
expressed in inhibitory interneurons and activates ERBB4 cell-
autonomously, causing a downregulation of NMDA receptor activity
in these cells (Vullhorst et al, 2015). In such a scenario, inhibition
of ERBB4 activity may indeed increase IPSCs, a hypothesis fitting to
our observations, for both spironolactone and lapatinib control
treatments. Overall, these findings indicate that altered NRG1/
ERBB4 signaling modulates inhibitory signaling, although different
adaptations may prevail in different brain regions and genetic
models as well as pharmacological treatments.
Our biochemical analysis implicates LIMK1 signaling, but not
ERK1/2 nor AKT1 as potential downstream effectors of spironolac-
tone treatment in Nrg1-tg mice. As a non-receptor protein serine/
threonine kinase, LIMK regulates synaptic spine morphology and
function by modulating cytoskeleton dynamics (Meng et al, 2002,
2004; Bennett, 2011). Further, LIMK1 has been linked to NRG1
signaling and SZ-relevant endophenotypes in a Nrg1-tg mouse
model (Yin et al, 2013). We show that phospho-LIMK1 levels were
upregulated in Nrg1-tg mice treated with spironolactone suggesting
that LIMK1 activity may possibly integrate spironolactone’s inhibi-
tory effect by promoting spine enlargement, and thus synapse
formation, through controlling actin cytoskeleton dynamics. Nrg1-tg
animals display subtle structural changes related to spine morphol-
ogy, that is, the number of bifurcated spines is increased (Agarwal
et al, 2014). Therefore, it might be possible that spironolactone
treatment reverts this structural endophenotype. Nonetheless, the
increased levels of p-LIMK1 rather favor a mechanism compensating
for the structural changes in Nrg1-tg mice, which may underlie
network disturbances in these animals, by stimulating structural
plasticity via increased LIMK1 activity. To further explore the mode-
of-action of spironolactone in the future, its impact on structural
plasticity should be addressed in additional studies.
Spironolactone has been developed as MR antagonist and was
clinically applied for decades as a potent and safe diuretic (Ogden
et al, 1961). As brain-expressed corticoid receptors are implicated in
modulating the stress response, spironolactone treatment has been
tested in the context of depression and was shown to increase moti-
vation and curiosity in mice (Wu et al, 2012). Moreover, anxiety
was partially improved in a small group of patients suffering from
bipolar disorder (Juruena et al, 2009) in good agreement with our
finding that spironolactone affects anxiety-related behavior in Nrg1-
tg mice. Acute spironolactone administration to healthy human
volunteers, however, reduced memory retrieval (Zhou et al, 2011;
Rimmele et al, 2013) and reportedly impaired recent fear memory
formation in mice (Zhou et al, 2011). Upon chronic administration
of spironolactone, however, we could not observe any detrimental
effects on cognitive performance in fear and working memory tests
in wild-type mice. However, spironolactone-treated Nrg1-tg mice
displayed a slightly reduced level of fear memory, which may be
partially dependent on anxiolytic actions of spironolactone or
decreased pain sensitivity in transgenic mice. Nonetheless, working
memory deficits of Nrg1-tg mice were rescued upon spironolactone
treatment.
Structure-function analysis using spironolactone metabolites and
second-generation analogues revealed that the intact structure of
spironolactone is paramount for inhibiting ERBB4 signaling activity.
We speculate that other structural modifications of spironolactone
may improve its selectivity for ERBB4 binding and concomitant inhi-
bition. Spironolactone may therefore also serve as a template for a
lead optimization process, which could produce a new molecular
entity with improved characteristics to inhibit ERBB4 signaling and
avoiding potentially adverse effects on the MR. Nonetheless, given
our observations and the safety profile of spironolactone, a clinical
study might be warranted to assess the chronic effects of spironolac-
tone treatment in SZ patients.
Materials and Methods
Plasmids
Gateway recombination cloning (Life Technologies) was applied for
generating plasmids. Each ORF cloned was PCR-amplified using the
Pwo proofreading DNA polymerase (Roche) and BP-recombined
into the pDONR/Zeo plasmid (Life Technologies) to yield an entry
vector, which was control-digested using BsrGI to release the insert,
and sequence-verified. The following human ORFs were cloned
using cDNA image clones ordered from Source BioScience: ERBB4
transcript variant JM-a/CYT-1 (Accession: BC112199), PIK3R1
(BC094795), GRB2 transcript variant 1 (BC000631), SHC1 transcript
variant 2 (BC014158), STAT5A (BC027036), and SRC transcription
variant 1 (BC051270). For EGFR, ERBB2, and ERBB3, entry vectors
were obtained from the human CCSB kinase collection available
from Addgene (Johannessen et al, 2010). Entry vectors were LR-
recombined into split TEV destination vectors [either pcDNA_attR1-
ORF-attR2-NTEV-tevS-GV-2xHA_DEST or pTag4C_attR1-ORF-attR2-
CTEV-2xHA_DEST, plasmids were described in detail before (Wehr
et al, 2006)] to yield expression vectors, which were control-
digested using BsrGI. The plasmids for Nrg1 type I b1a and rat Nrg1
type III b1a have been described before (Wehr et al, 2006).
The oligonucleotides used for cloning are shown in the
Appendix Table S2.
Cell culture
PC12 Tet-Off cells (Clontech, 631134, termed PC12 cells for simplic-
ity) and their derivatives stably expressing Nrg1 were cultured in
low glucose DMEM medium (1 g/l, Lonza) supplemented with 10%
FCS, 5% HS, 50 lg penicillin, 50 lg streptomycin and GlutaMAX
(Life Technologies) at 37°C, and 5% CO2. T-47D cells (ATCC:HTB-
133) were grown RPMI-1640 (Life Technologies) supplemented with
0.2 units/ml bovine insulin (Sigma), 10% FCS, 50 lg penicillin,
50 lg streptomycin and GlutaMAX (all Life Technologies) at 37°C,
and 5% CO2. PC12 cells were grown on poly-L-lysine-coated
surfaces for both maintenance and experiments; T-47D cells were
only grown on poly-L-lysine-coated surfaces for experiments. Cell
lines were negative for mycoplasma contamination.
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Generation of PC12 cells stably expressing Nrg1
1 Mio PC12 cells were either transfected with 10 lg of a Nrg1 type I
b1a plasmid or Nrg1 type III b1a plasmid using Lipofectamine 2000.
Following an initial expression of 24 h, 400 lg/ml G418 was applied
to select stable clones as each Nrg1 plasmid harbors a neomycin
resistance gene for selection in mammalian cells. After 2 weeks of
culturing, visible PC12 cell clones were transferred into a single well
of a 24-well plate. Following to a recovery and expansion phase,
stable Nrg1 expression was validated in a split TEV-based ERBB4-
PIK3R1 co-culture assay. Positive clones were also verified by
Western blot analysis.
Protein lysates and Western blotting
PC12 cells were transfected with indicated plasmids using Lipo-
fectamine 2000 (Life Technologies). After 24 h of expression,
cells were treated as indicated and lysed in a 1% Triton-X lysis
buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 1% Triton X-100,
1 mM EGTA) supplemented with 10 mM NaF, 1 mM Na2VO4,
1 mM ZnCl2 4.5 mM Na4P207, as phosphatase inhibitors, and the
complete protease inhibitor cocktail (Roche). Lysates from T-47D
cells were analyzed for endogenous proteins only. For the analy-
sis of cytosolic proteins, cell extracts were spun for 10 min at
4°C at 17,000 g.
For the biochemical analysis of spironolactone-treated mice (for
a precise description of the injection paradigm, see subheading
“Mouse behavior analysis”, “Spironolactone treatment”), vehicle
control or spironolactone was subcutaneously injected daily for
21 days into age-matched (11–13 weeks) male mice prior to prepa-
ration of the mouse prefrontal cortex (n = 2 per genotype and treat-
ment). For the generation of lysates, the isolated tissue was
immediately placed into cooled (4°C) sucrose buffer (320 mM
sucrose, 10 mM Tris–HCl, 1 mM NaHCO3, 1 mM MgCl2, supple-
mented with 10 mM NaF, 1 mM Na2VO4, 1 mM ZnCl2, 4.5 mM
Na4P207 as phosphatase inhibitors, and the complete protease inhi-
bitor cocktail (Roche)), homogenized using an ultra-turrax (IKA
GmbH, Staufen, Germany), sonicated (3 pulses for 10 s), and dena-
tured for 10 min at 70°C in LDS sample buffer.
Protein gels were run using the Mini-PROTEAN Tetra Elec-
trophoresis System (Bio-Rad), and gels were blotted using the
Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad). Detection
of proteins was performed by Western blot analysis using chemi-
luminescence (Western Lightning! Plus-ECL, PerkinElmer).
Western blots were probed with antibodies at dilutions as shown
in the Appendix Table S3. Each blot was replicated two times.
Western blots were densitometrically quantified using ImageJ
following the protocol openly accessible at lukemiller.org (http://
lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-
with-image-j/).
Immunofluorescence staining of PC12 cells
1 Mio PC12 cells were plated per well onto poly-L-lysine (PLL)-
coated coverslips in a 6-well plate at day 1. At day 2, cells were
transfected with ERBB4-NTEV-tevs-GV or ERBB4_1-685-NTEV-tevS-
GV. At day 3, cells were gently washed twice by adding and remov-
ing 1× TBS (50 ll per coverslip), fixed in cold 4% PFA for 10 min,
washed twice with 1× TBS, and permeabilized in TBS/0.1% Triton
X-100 for 5 min. Then, cells were washed again three times in 1×
TBS and blocked in blocking buffer (3% BSA, 0.1% Triton X-100 in
1× TBS) for 1 h at room temperature. Primary antibodies diluted in
blocking buffer and cells were incubated for 1 h at room tempera-
ture. Following three washes in TBS, cells were incubated with a
secondary antibody (Alexa 594 anti-rat, 1:500, Abcam, ab150160)
diluted in blocking buffer for 1 h at room temperature. Coverslips
were washed three times in 1× PBS, once quickly dipped into ddH2O
to remove traces of salt, mounted on microscope slides, and sealed
with ProLong Gold Antifade Mountant with Dapi (ThermoFisher
Scienctific, P36935). Slides were stored at 4°C before imaged on a
Zeiss Observer Z.1 microscope.
Compound screening and validation
Cell-based split TEV assay to monitor ERBB4 activity
The split TEV method is based on the functional complementation
of two previously inactive TEV protease fragments denoted NTEV
and CTEV fused to interacting proteins. It has been shown to
robustly and sensitively quantify protein–protein interactions and
receptor activities, as proven before for the ERBB4 receptor and the
regulatory adapter subunits of the PI3K, PIK3R1, and PIK3R2 (Wehr
et al, 2006, 2008). Recently, the split TEV method was also success-
fully applied to genomewide RNAi screening in Drosophila cell
culture, supporting its applicability to high-throughput applications
(Wehr et al, 2013).
For our HTS-compatible split TEV assay approach, human full-
length ERBB4-Cyt1 was fused to the NTEV fragment, a TEV
protease cleavage site (tevS) and the artificial co-transcriptional
activator Gal4-VP16 (ERBB4-NTEV-tevS-GV); human PIK3R1 was
fused to the CTEV fragment (PIK3R1-CTEV) (Fig 1A). Upon
ERBB4 activation, PIK3R1 is recruited to the receptor resulting in
a reconstituted protease activity that cleaves off GV. In turn,
released GV translocates to the nucleus and binds to upstream
activating sequences (UAS) to activate the transcription of a fire-
fly luciferase reporter gene (Fig 1A). A constitutively expressed
Renilla luciferase driven under the control of the human thymi-
dine kinase (TK) promoter was used as control to address off-
target effects related to toxicity.
Compound library
For small molecule screening, the NIH-NCC Clinical Collection
library (sets NCC-003 and NCC-201) was used containing 727 small
molecules that are FDA-approved and have a history in clinical
applications (www.nihclinicalcollection.com). A Hamilton Labstar
robot connected to 37 and 4°C incubators for cell incubation and
compound storage and application (Cytomat automated incubator,
ThermoScientific) and to a luciferase reader (Berthold Technologies)
was used to automatically perform the screening. Batch 1 (com-
pounds 1–320) was run in quadruplets, batch 2 (compounds 321–
727) in triplicates. Each batch was screened three times.
Transfection of cells
To equally transfect large amounts of cells, PC12 cells were trans-
fected with the split TEV assay components in solution. For one 96-
well plate, 4 × 106 PC12 cells were harvested and diluted in 5 ml
assay medium (phenol red-free DMEM (low glucose, Life
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Technologies), 10% FCS, 5% HS, no antibiotics). The split TEV
assay plasmids (2 lg pcDNA3_ERBB4-NTEV-tevS-GV-2xHA, 2 lg
pTag4C_PIK3R1-CTEV-2xHA, 2 lg p5xUAS_firefly luciferase, 2 lg
pTK_Renilla luciferase, and 0.5 lg pECFP-C1 for examining trans-
fection efficiency) were diluted in 2.5 ml Opti-MEM (Life Techno-
logies) and vortexed. In parallel, 20 ll of the transfection reagent
Lipofectamine 2000 was diluted in 2.5 ml Opti-MEM and vortexed.
Both Opti-MEM aliquots were mixed, vortexed, and incubated for
20 min at room temperature, followed by carefully mixing the
DNA/Lipofectamine/Opti-MEM solution with the PC12 cells and
incubating the cell suspension at 37°C and 5% CO2 for 2 h without
shaking.
Plating the cells
For plating of one 96-well plate, 10 ml suspension, containing the
4 × 106 in solution-transfected cells, was placed in the bubble
paddle reservoir of the Hamilton Cellstar robot. 100 ll was seeded
per 96-well using the 96-tip pipetting head. The homogeneity of the
cell suspension was guaranteed over time by mild stirring using the
paddling device inside the reservoir. For five plates each, 50 ml of
additional cell suspension was used to allow for losses of inaccessi-
ble volume. After seeding, plates were transferred and stored in the
Cytomat device at 37°C and 5% CO2.
Addition of compounds
The cells were allowed to express the plasmids for 24 h before
compounds were added. Proper expression and transfection effi-
ciency were verified by ECFP expression on a clear control plate.
The compounds were applied in a final concentration of 10 lM
using DMSO as diluent. Sixteen positions per 96-well plate (i.e.,
columns A and H) were reserved for controls; in detail, four wells
each were taken for positive controls (stimulated with 10 ng/ml
EGFld (Reprokine, RKQ02297) in DMSO, 96-well positions A1 to
D1), baseline controls (DMSO only, 96-well positions E1 to H1),
negative controls I (100 nM CI-1033 (Canertinib dihydrochloride,
Axon, 1433) in DMSO, 96-well positions A12-D12), and negative
controls II (10 lM lapatinib (Lapatinib ditosylate, Axon, 1395) in
DMSO, 96-well positions E12 to H12). Thirty minutes later, 10,000
Nrg1-expressing PC12 cells in 100 ll assay medium were seeded on
top. 24 h after addition of the compounds, the cells were lysed using
40 ll Passive Lysis buffer (Promega) and subjected to a Dual
Luciferase Assay (Promega) according to the manufacturer’s
instructions. The data were analyzed in R Bioconductor using the
package cellHTS2 (http://www.bioconductor.org/packages/devel/
bioc/html/cellHTS2.html), assessed using the z-score, and visual-
ized using the program Mondrian (http://stats.math.uni-augsb
urg.de/mondrian/).
Dose–response luciferase assays for validation
Individually re-screened candidates were validated using a dose–
response assay. PC12 cells were batch-transfected as described in
the section “Transfection of cells”, manually plated, and incubated
for 24 h at 37°C and 5% CO2. Candidate small molecules were
prepared in a series of dilutions using DMSO as diluent and ranging
from 0.0001 to 100 lM at final concentrations, thus covering at least
five orders of magnitude. Candidate dilutions were added, followed
by the addition of 10,000 Nrg1-expressing cells in 100 ll volume
30 min later. Cells were lysed in 40 ll Passive Lysis Buffer and
analyzed in a Dual Luciferase Assay. Data were analyzed in Excel
and GraphPad Prism. For single-culture assays that used EGFld as
stimulus, 100 ll assay medium containing EGFld (f.c. 10 ng/ml)
was administered. The following candidates were analyzed in dose–
response assays: spironolactone (Sigma-Aldrich, S3378), eplen-
renone (Sigma-Aldrich, E6657), canrenone (Santa Cruz Biotechnol-
ogy, sc-205616), 7a-thiomethyl-spironolactone (Santa Cruz
Biotechnology, sc-207187). Dose–response assays were run in six
replicates per concentration and repeated at least two times. Data
are shown as mean, and error bars represent SEM.
Electrophysiology
300-lm-thick transverse slices comprising the medial prefrontal
cortex (mPFC) area were prepared from 7- to 8-week-old C57Bl/6
mice as described previously (Teng et al, 2013; Agarwal et al,
2014). All recordings were performed in cortical layer V projection
neurons. The bath solution consisted of oxygenated artificial cere-
brospinal fluid (ACSF) containing NaCl 126 mM, KCl 3 mM,
NaH2PO4 1.25 mM, MgSO4 1 mM, NaHCO3 26 mM, CaCl2 2 mM,
glucose 10 mM, and the pH 7.2 adjusted with NaOH. Spontaneous
GABAergic inhibitory postsynaptic currents (sIPSC) and evoked
GABAergic inhibitory postsynaptic currents (eIPSC) were
recorded at a holding potential of !70 mV in the presence of
6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 lM) and DL-2-
amino-5-phosphonovaleric acid (D-APV, 50 lM). Glass pipettes
were filled with the solution containing: KCl 140 mM, MgCl2 2 mM,
CaCl2 1 mM, Na2GTP 0.5 mM, Na2ATP 4 mM, EGTA 10 mM,
HEPES 10 mM. Patches with a series resistance of > 25 MO, a
membrane resistance of < 0.8 GO, or leak currents of > 150 pA
were excluded. Biphasic rectangular electric pulses (10 ms, 100–
300 lA) were applied to layer I of the prelimbic area of mPFC
through another glass pipette filled with ACSF. Synaptic currents
were acquired at 20 kHz and filtered at 6 kHz, with a Digidata 1440
ADC-converter coupled to a Multiclamp 700B amplifier (Molecular
Devices, USA). Data acquisition was performed using pClamp10
software (Molecular Devices). MiniAnalysis 6.0.9 (Synaptosoft Inc.,
Decatur, USA) and pClamp10.1 were used for amplitude and
frequency analysis of sIPSCs and eIPSCs, respectively. Paired
Student’s t-test was used for statistical analysis.
Mouse behavior analysis
For behavioral testing, age-matched male mice (8–16 weeks) on
C57Bl/6 background that constitutively overexpress the 2xHA-
tagged Nrg1 type III b1a isoform (Nrg1-tg) under the control of the
mouse Thy1.2 promoter (Velanac et al, 2012) and their wild-type
(wt) littermates as controls were used. Animals were group-housed
in the same ventilated sound-attenuated rooms under a 12-h light/
12-h dark schedule (lights on at 8:00 am) at an ambient temperature
of 21°C with food and water available ad libitum. One week prior to
experiments, mice were separated into single cages and habituated
to the experimental rooms. To minimize the influence of the circa-
dian rhythm on drug actions, the treatment groups were analyzed at
balanced time points during the light phase. The investigators for
behavioral tests were blind to genotypes and/or spironolactone
administration. All animal experiments were conducted in accor-
dance with NIH principles of laboratory animal care and were
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approved by the Government of Lower Saxony, Germany, in accor-
dance with the German Animal Protection Law.
Spironolactone treatment
50 mg of Spironolactone (Sigma-Aldrich) was initially dissolved in
DMSO and suspended in 10 ml of 0.9% NaCl, 1% DMSO, and
0.002% Tween!20. Spironolactone (5 mg/ml) and a vehicle control
(0.9% NaCl, 1% DMSO, and 0.002% Tween!20) were subcuta-
neously injected with a 50 mg/kg dose daily (e.g., corresponding to
0.3 ml injection volume of a mouse with 30 g weight) for 3 weeks
prior to behavioral testing (n = 12 per genotype and per treatment).
Treatment was continued throughout the behavioral analysis
period. To avoid injection-induced stress prior to behavioral testing,
mice were injected in the afternoon, after the entire cohort has
completed the behavioral paradigm.
Calculation of spironolactone dosage
The calculated daily dosage of 50 mg/kg/day spironolactone for
mice is based on the following assumptions. Patients are routinely
treated with 400 mg/day spironolactone (Aldactone 100, Riemser
Pharma; spironolactone 100, Ratiopharm). Dosages of 50 to
100 mg/day were administered to patients in long-term treatments
(Juruena et al, 2009). The dosage of 400 mg/80 kg patient body
weight per day is equal to 5 mg/kg/day. Human doses are
converted to mouse doses using the body surface area normalization
method, which integrates various aspects of biological parameters
including basal metabolism, blood volume, caloric expenditure, and
oxygen utilization (Reagan-Shaw et al, 2008). For the calculation of
the mouse dose (mg/kg), the human dose (mg/kg) is multiplied by
the human Km/mouse Km, where the human Km = 37 and the mouse
Km = 3. Therefore, mice should be treated with a 12-fold higher
dose. The chosen dosage of 50 mg/kg/day is slightly below the
calculated maximum dose of 61.7 mg/kg/day [(400 mg/80 kg)*
(37/3)/day]. The lC50 of spironolactone is > 1,000 mg/kg/day.
Spironolactone is FDA-approved, used in patients for decades, and
shows no major side effect in treated mice.
Behavioral tests applied for mouse behavior analysis
Open field and hole board Spontaneous locomotor activity was
verified in the open-field test using a Plexiglas box (45 × 45 ×
55 cm). The same test arena was modified with a floor insert
containing 16 symmetrically allocated holes for the hole board test.
During a 10-min testing session, mouse behavior was monitored by
infrared sensors and recorded by the ActiMot software (TSE, Bad
Homburg, Germany). Levels of urination (scored in events) and
defecation (scored as feci in events) were determined manually
during the open-field test.
Light–dark preference The light–dark preference test was
conducted in a plastic chamber divided into two compartments of
same size, with one having black and the second one having trans-
parent Plexiglas walls. A door-like opening in the center of the sepa-
rating wall allowed transitions between both compartments. For
testing, each mouse was placed into the light compartment facing
away from the door and left undisturbed. The latency to enter the
dark compartment, the time spent in the dark compartment, and
the number of crossings between the compartments were monitored
for 5 min using the AnyMaze software. Mice that did not enter the
dark compartment within 10 min were excluded from the experi-
ment. After each session, the chambers were cleaned with 70%
ethanol.
Y-maze The assessment of working memory was performed using
an in-house made Y-shaped runway. Animals were placed individu-
ally into the Y-maze facing the wall and allowed to explore the maze
for 10 min. The experiment was video recorded. The number of arm
choices (as a measure of activity) and the percent of alterations
(choices of a “novel” arm, i.e., when animals chose a different arm
as before is regarded as a measure of working memory) were scored
and analyzed. To avoid any olfactory cues, the apparatus was
cleaned with 70% ethanol between animals.
Tail suspension test Mice were manually suspended upside down
for 6 min by attaching them to a fixed rod using an adhesive tape
positioned at the tip of the tail. The escape motivation of a mouse
was measured as the time spent active, video recorded, and scored
offline.
Prepulse inhibition (PPI) The startle response was measured using a
two test cabinet (SR-LAB, San Diego Instruments) using a protocol
as described in Brzózka et al (2010).
Fear conditioning Fear memory assessment that is measured by
freezing behavior was performed using the Ugo Basile Fear Condi-
tioning System (Varese, Italy). For conditioning, mice were placed
into the animal box (furnished with a stainless shock grid floor and
striped black-white walls) and positioned into an isolation cubicle
equipped with a lamp, a loudspeaker and infrared camera. For
conditioning, striped black-white walls were inserted into the
animal box. The conditioning and fear memory assessment were
performed as described in Brzózka et al (2010).
Hot plate Pain sensitivity was measured in the hot plate test.
Animals were placed onto a metal plate preheated to 52°C. The
latency to the first reaction (hind paw licking or jumping) was
scored manually. Immediately after the first response, mice were
placed onto another metal plate (not heated) to allow cooling their
paws.
Statistical analysis
Statistical significance was determined using Microsoft Excel, IBM
SPSS Statistics v22 and GraphPad Prism 5.0 software. Data are
presented as means " SD or SEM as indicated (n ≥ 3, for luciferase
assays n = 6). For behavioral experiments, Student’s t-tests were
used for comparing two data samples. If the experimental setup
required a paired data analysis, paired Student’s t-test or paired
Wilcoxon signed ranks test was used for comparing two normally or
not-normally distributed data samples, respectively. Two-way
ANOVA with Bonferroni post hoc test was used for the analysis of
three or more samples. Two-way ANCOVA was used for the age-
corrected analyses of open-field, Y-maze and light–dark preference
tests. Repeated-measures ANOVA was used to analyze the effects of
treatment in the PPI analyses. The robustness of cell-based assays
was assessed using the Z’ factor. Data from screening were analyzed
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using the cellHTS2 package available for R and evaluated using the
z-score.
Expanded View for this article is available online.
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Expanded View Figures
▸Figure EV1. A co-culture assay based on the split TEV technique to monitor NRG1-ERBB4 signaling activity.A PC12 cell lines stably expressing mouse Nrg1 type I b1a and Nrg1 type III b1a. PC12 cells were stably transfected with a plasmid encoding Nrg1 type I b1a or type
III b1a, and Nrg1 expression was verified by Western blot analysis using an Nrg1 antibody that detects the b1a C-terminus.
B Co-culturing two populations of PC12 cells. Cell population A was transfected with a nuclear localized EYFP (EYFPnuc), and cell population B was transfected with
ECFP. Following to an initial expression of 24 h, cells were mixed and imaged 24 h later. Scale bar, 100 lm.
C ERBB4-PIK3R1 dose–response assay using EGFld as stimulus. Three independent experiments using the ERBB4-PIK3R1/EGFld assay are shown. The EC50 value for
this assay is at 1 ng/ml EGFld. The inset depicts the Z’ factors for each individual assay.
D Lapatinib antagonizes ERBB4-PIK3R1 signaling in a dose-dependent manner. Per 96-well, 40,000 split TEV assay cells were incubated with increasing amounts of
lapatinib, followed by a stimulation using 10 ng/ml EGFld.
E, F CI-1033 antagonizes ERBB4-PIK3R1 signaling in a dose-dependent manner. Per 96-well, 40,000 split TEV assay cells were incubated with increasing amounts of
CI-1033, followed by either co-plating 10,000 Nrg1-expressing cells (E) or stimulation with 10 ng/ml EGFld (F).
Data information: Fluc, firefly luciferase activity (black lines); Rluc, Renilla luciferase activity (gray lines, indicating toxicity levels). Data are shown as mean, and error bars
represent SEM, n = 6. The insets depict IC50 values in lM.
Source data are available online for this figure.
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Figure EV2. Spironolactone is the top candidate recovered from the co-culture screen.
A Graphic visualization of the primary screen data of the NIH-NCC library, set 2. All counts (407 compounds and 96 controls) from the Nrg1-ERBB4-PIK3R1 split TEV
compound screen were plotted against the z-score using Mondrian, with pathway activators displaying high values and inhibitors low values. For the secondary
analysis, we selected all candidates that were at least three standard deviations away from the mean. EGFld-positive and lapatinib/CI-1033-negative controls are
shown in red.
B, C Spironolactone does not affect activities of control assays. Neither the activity of the GAL4/UAS system (B) nor the activity of the TEV protease (C) was affected in
spironolactone dose-dependent assays. For the GAL4/UAS assay, GAL4-VP16 (GV) and 10×UAS firefly luciferase (10×UAS-Fluc) plasmids were transfected into PC12
cells. For TEV protease activity assays, a transmembrane-localized TEV protease (TM-TEV) was expressed in PC12 cells with a transmembrane-localized and TEV-
cleavable GV (TM-tevS-GV) and the 10×UAS-Fluc reporter. 10 ng/ll EGFld was applied as Nrg1 stimulus. In both control assays, the assay activity (firefly luciferase,
black lines) was similar to the toxicity levels (gray lines). Data are shown as mean, a nd error bars represent SEM, n = 6. The insets depict IC50 values in lM.
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Figure EV3. Truncated ERBB4 dimers are not inhibited by spironolactone.
A Full-length and truncated ERBB4 split TEV fusions localize to the cell membrane. PC12 cells were transfected with a full-length human ERBB4 split TEV fusion
(ERBB4-NTEV-tevS-GV-2HA) (left panels) or a truncated human ERBB4 split TEV fusion (ERBB4_1–685_NTEV-tevS-GV-2HA) that covers residues 1–685 and contains
the transmembrane domain but lacks the intracellular domain (right panels). Cells were allowed to express the fusion proteins for 24 h, fixed, and stained for the
double HA (2HA) tag. Arrowheads indicate expression of full-length and truncated ERBB4 at the membrane. Scale bars, 5 lm.
B Both full-length and truncated ERBB4 dimerize in split TEV assays when stimulated with extracellular EGFld. PC12 cells were transfected with split TEV pairs of
ERBB4-NTEV-tevS-GV/-CTEV and ERBB4_1–685_NTEV-tevS-GV/-CTEV, starved overnight, stimulated with EGFld (10 ng/ml) or mock-stimulated (unstim), incubated for
20 h, lysed, and subjected to a luciferase assay. Fluc, firefly luciferase activity.
C Spironolactone-mediated inhibition of the ERBB4 dimerization requires the intracellular domain. Truncated ERBB4 receptor molecules (amino acids 1–685) were
fused to N- and CTEV moieties, transfected into PC12 cells and assayed in a spironolactone dose-dependent assay in the presence of 10 ng/ml EGFld using the split
TEV technique. Spironolactone had no inhibitory effect, as the assay activity (Fluc, firefly luciferase, black line) was comparable to the toxicity levels (Rluc, Renilla
luciferase, gray line). The inset depicts the IC50 value in lM.
D Spironolactone reduces ERBB4 levels. PC12 cells were transfected with the split TEV assay plasmid ERBB4-NTEV-tevS-GV (where indicated), stimulated with 10 ng/ml
EGFld, 10 lM lapatinib, and 10 lM spironolactone for 1 h as indicated. Cell lysates were probed for ERBB4 phosphorylation levels at Tyr1056. Note that
spironolactone reduces but not abolishes the phosphorylation levels.
Data information: Data are shown as mean, and error bars represent SEM, n = 6.
Source data are available online for this figure.
▸Figure EV4. Collection of ERBB dimer dose–response assays assessing the target specificity of spironolactone treatment.A–J Fluc, firefly luciferase activity reporting ERBB dimer assay activity (black lines) using the split TEV assay technique; Rluc, Renilla luciferase activity (gray lines)
assessing viability. EGFld (10 ng/ml) was applied as stimulus unless stated otherwise. Data are shown as mean, and error bars represent SEM, n = 6. The insets
depict IC50 values in lM. The following combinations were tested
(X-NTEV-tevS-GV with Y-CTEV): (A) ERBB1 (EGFR)/ERBB1, (B) ERBB1/ERBB2, (C) ERBB1/ERBB3, (D) ERBB1/ERBB4, (E) ERBB2/ERBB2, (F) ERBB2/ERBB3, (G) ERBB2/ERBB4,
(H) ERBB3/ERBB3, (I) ERBB3/ERBB4, (J) EGFR/EGFR with 100 ng/ml EGF as stimulus.
◀
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▸Figure EV5. Behavioral analysis of Nrg1-tg and wt mice upon spironolactone treatment.A Experimental design to test PPI deficits in Nrg1-tg mice. Nrg1-tg mice and wt controls were tested in the PPI test 1 day prior to chronic spironolactone treatment.
One day after the last injection, transgenic and control mice were submitted to the PPI paradigm.
B Naïve Nrg1-tg displayed strong PPI deficits prior to chronic spironolactone treatment (effect of genotype F1,33 = 25.74; P < 0.0001, two-way ANOVA, and Bonferroni
post hoc test: ***P < 0.0001, ***P = 0.0002, ***P = 0.0003 for prepulse intensities 70, 75 and 80 dB, respectively).
C Chronic treatment with spironolactone improved PPI in transgenic animals (effect of treatment F1,20 = 9.63; P = 0.0056, two-way ANOVA), with the most prominent
effect when a prepulse of 70 dB was presented (**P = 0.0060, Bonferroni test; 75 and 80 dB were P = 0.3067 and P = 0.1077, respectively, Bonferroni test).
D Spironolactone treatment did not influenced PPI in wt controls (effect of treatment F1,26 = 0.14; P = 0.7096, two-way ANOVA).
E Nrg-tg mice spent less time in the center of the open-field arena (effect of genotype F1,44 = 6.69; P = 0.0131, two-way ANOVA). Spironolactone treatment did not
influence this parameter (F1,44 = 0.12; P = 0.7290, two-way ANOVA).
F In the open-field test, Nrg1-tg mice showed increased defecation (effect of genotype F1,44 = 10.35; P = 0.0024, two-way ANOVA), which was significant in vehicle-
treated animals (*P = 0.0310; Bonferroni test), but not in spironolactone-treated animals (P = 0.0967). There was no effect of treatment observed (F1,44 = 0.65;
P = 0.4256, two-way ANOVA).
G Transgenic animals displayed more frequent urination than wt controls (effect of genotype F1,44 = 14.14; P = 0.0005, two-way ANOVA) in both vehicle and
spironolactone-treated animals (*P = 0.0451 for vehicle-treated and *P = 0.0100 for spironolactone-treated groups, Bonferroni test), without effect of treatment
(F1,44 = 0.17; P = 0.6781, two-way ANOVA).
H In the light–dark preference test, transgenic mice performed similar number of transitions between light and dark compartment when compared to wt controls
(effect of genotype F1,41 = 0.05; P = 0.8227, two-way ANOVA).
I In the tail suspension test, transgenic mice were more active than wt controls. The effect was independent of treatment (effect of genotype F1,44 = 35.16; P < 0.0001,
two-way ANOVA). The Bonferroni test showed a significant difference between genotypes both in vehicle and spironolactone-treated groups (***P < 0.0001 and
**P = 0.0067, respectively).
J Nrg1-tg animals displayed an increased activity in the Y-maze test as they performed more arm choices (effect of genotype F1,44 = 14.56; P = 0.0004, two-way
ANOVA), with *P = 0.0301 in vehicle-treated and *P = 0.0127 in spironolactone-treated groups (Bonferroni test). There was no effect of treatment (F1,44 = 0.39;
P = 0.5367, two-way ANOVA).
K Naïve Nrg1-tg mice did not display impairments in the fear conditioning test. However, transgenic animals treated with spironolactone showed a tendency toward
lower freezing rate during contextual memory test (P = 0.0885; Mann–Whitney test). A two-way ANOVA yielded a substantial, but not significant, interaction in the
contextual memory test (F1,44 = 3.56: P = 0.0657); but neither an effect of genotype (F1,44 = 0.96; P = 0.3315) nor of treatment (F1,44 = 1.16; P = 0.2880) was
detected. Naïve Nrg1-tg showed an increased freezing rate during baseline recordings prior to the cue test (##P = 0.0351, Mann–Whitney test); this difference
between the genotypes was not observed in groups treated with spironolactone.
L In the hot plate test, Nrg1-tg mice showed an increased latency to the first reaction (effect of genotype F1,44 = 12.47: P = 0.0010; two-way ANOVA), which was most
prominent in the group treated with spironolactone (**P = 0.0024, Bonferroni test) but not in vehicle-treated groups (P = 0.2662, Bonferroni test).
M Spironolactone treatment did not influence PPI in wt mice (effect of treatment F1,22 = 0.00; P = 0.9461, two-way ANOVA).
Data information: Data are shown as mean, and error bars represent SEM; n.s., not significant; Spiro, spironolactone; pre-Spiro, data collected before spironolactone
treatment. n = 12 per genotype and treatment with an exception in (F): Nrg1-tg vehicle, n = 11; Nrg1-tg Spiro, n = 10; wt vehicle, n = 12; wt Spiro, n = 12).
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Appendix Fig S1. Summary of the validation strategy for drug repurposing performed on 
the NRG1-ERBB4-PI3K schizophrenia risk pathway. 
To identify small molecule modulators of NRG1-ERBB4 signaling in the context of drug 
repurposing and schizophrenia, the NIH-NCC compound collection was subjected to a cell-
based co-culture assay screening approach using the split TEV technique as readout. Hits 
recovered from the screen were analyzed using the computational method cellHTS2 and 
validated using a consecutive analysis of various individual assays as depicted. The paradigm 
tested is shown on the left, the molecular target assessed or assay applied on the right. 
 
 
Appendix Fig S2. Protein expression analysis reveals strong Erbb4, but no detectable Egfr 
expression in the adult mouse brain. 
(A) Erbb4 protein expression is increased in prefrontal cortex, hippocampus and striatum. 
Expression data is normalized to overall protein expression and values are log2-transformed, 
positive values are plotted. Data is extracted from http://www.mousebrainproteome.com/ 
(Sharma et al, 2015). 
(B) Egfr is not expressed in prefrontal cortex of adult WT and Nrg1-tg mice. Lysates from NIH-
3T3 cells (fibroblast-derived mouse cell line with low Egfr expression) and prefrontal cortex 
(both WT and Nrg1-tg mice, P60) were subjected to Western Blotting and probed for indicated 




Appendix Fig S3. Covariate analysis revealed no significant effect of age on the treatment 
response. 
(A) Two-way ANCOVA considering age groups (juvenile/adult) as covariate did not report a 
significant genotype x treatment interaction (F(1,43)=2.174; p=0.148). Related to Fig 5B. There 
were no overall differences between juvenile and adult mice within each experimental 
condition (all t-tests p≥0.199).  
(B) Two-way ANCOVA considering age groups (juvenile/adult) as covariate reported a 
significant genotype x treatment interaction (F(1,40)=4.838; p=0.034). Related to Fig 5E. 
Absence of statistically significant age-related effects on the light-dark preference test. There 
were no overall differences between juvenile and adult mice within each experimental 
condition (all t-tests p≥0.221).  
(C) Two-way ANCOVA considering age groups (juvenile/adult) as covariate reported a 
suggestive genotype x treatment interaction (F(1,43)=3.528; p=0.067). Related to Fig 5F. 
There were no overall differences between juvenile and adult mice within each experimental 
condition (all t-tests p≥0.209).  
(D) Pairwise analyses revealed also for PPI no significant differences between juvenile and 
adult mice within each experimental condition (all t-tests p≥0.107). Related to Fig 5G. 
Data are shown as mean, error bars represent SEM. *, p<0.05; Spiro, spironolactone; Veh, 
vehicle; juvenile mice were defined as 8-11 weeks old, adult mice were defined as 12-16 
weeks old. 
For (A) and (C), juvenile Nrg1-tg vehicle, n=5, adult Nrg1-tg vehicle, n=7; juvenile Nrg1-tg 
Spiro, n=5; adult Nrg1-tg Spiro, n=7; juvenile wt Vehicle, n=8; adult wt vehicle, n=4; 
juvenile wt Spiro, n=7; adult wt Spiro, n=5. 
For (B), juvenile Nrg1-tg vehicle, n=5, adult Nrg1-tg vehicle, n=6; juvenile Nrg1-tg Spiro, 
n=4; adult Nrg1-tg Spiro, n=6; juvenile wt Vehicle, n=8; adult wt vehicle, n=4; juvenile wt 
Spiro, n=7; adult wt Spiro, n=5; 
For (D), juvenile Nrg1-tg vehicle, n=4, adult Nrg1-tg vehicle, n=7; juvenile Nrg1-tg Spiro, 
n=5; adult Nrg1-tg Spiro, n=7. 
   
Appendix Table S1. Final hit list of approved drugs. 
Rank Z-score NCC_Sample_ID Pubchem_CID Compound_name, 
synonyms 
1 9.25 SAM002264648 5833 Spironolactone 
2 7.97 SAM001246651 60699 Topotecan HCl 
3 6.59 SAM001246973 2690 CGS 15943 
4 6.52 SAM002264631 4828 Pindolol 
5 5.88 SAM001246964 23581797 3'-Deoxydenosine 
6 5.88 SAM001246573 23581791 Vardenafil citrate 
7 4.7 SAM001246669 2161 Amlexanox 
8 4.3 SAM002699899 5362129 Ramipril 
9 4.26 SAM001246548 3749 Irbesartan 
10 3.82 SAM002589959 3003 Betamethasone 
11 3.13 SAM001246805 11693521 Telithromycin 
12 3 SAM002548951 1349907 Methimazole 
13 -3.6 SAM001246679 3793 Itraconazole 
14 -3.5 SAM001246526 20279 2-Chloro-2'-
deoxyadenosine 
15 -3.45 SAM002264605 65327 Norpramin 
16 -3.45 SAM001246775 2378 Bifonazole 
17 -4.63 SAM002548959 4030 Mebendazole 
18 -5.48 SAM002589939 2082 Albendazole 
 
The final hit list contains candidates that score at least 3 standard deviations (measured as z-








































The oligonucleotides listed above were used for cloning of open reading frames (ORFs) using 
Gateway recombination cloning (attB1 and attB2 sites are underlined). The oligonucleotide 
names contain the HGNC nomenclature of human ORFs cloned. 
 
  
Appendix Table S3. List of antibodies used. 
Antibody Species Dilution Experiment Source 
Catalog 
Number 
Akt rabbit 1:1000 WB 
Cell Signaling 
Technology 9272 
EGFR (A-10) mouse 1:500 WB 
Santa Cruz 
Biotechnology sc-373746 
ErbB4 (E200) rabbit 1:1000 WB Abcam ab32375 
HA (clone 3F10) rat 1:500 ICC Roche 
 11 867 
423 001 




20) rabbit 1:1000 WB 
Santa Cruz 
Biotechnology sc-348 
p44/42 MAPK (Erk1/2) 




(D9E) rabbit 1:1000 WB 
Cell Signaling 
Technology 4060 















(D13.14.4E) rabbit 1:2000 WB 
Cell Signaling 
Technology 4370 
Tubulin mouse 1:2000 WB Sigma T 5168 
WB, Western Blot; ICC, immunocytochemistry. 
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Abstract
Receptor tyrosine kinases (RTKs) play key roles in various aspects of cell biology, including cell-to-cell communication, 
proliferation and differentiation, survival, and tissue homeostasis, and have been implicated in various diseases including 
cancer and neurodevelopmental disorders. Ligand-activated RTKs recruit adapter proteins through a phosphotyrosine (p-Tyr) 
motif that is present on the RTK and a p-Tyr-binding domain, like the Src homology 2 (SH2) domain found in adapter 
proteins. Notably, numerous combinations of RTK/adapter combinations exist, making it challenging to compare receptor 
activities in standardised assays. In cell-based assays, a regulated adapter recruitment can be investigated using genetically 
encoded protein–protein interaction detection methods, such as the split TEV biosensor assay. Here, we applied the split 
TEV technique to robustly monitor the dynamic recruitment of both naturally occurring full-length adapters and artificial 
adapters, which are formed of clustered SH2 domains. The applicability of this approach was tested for RTKs from various 
subfamilies including the epidermal growth factor (ERBB) family, the insulin receptor (INSR) family, and the hepatocyte 
growth factor receptor (HGFR) family. Best signal-to-noise ratios of ligand-activated RTK receptor activation was obtained 
when clustered SH2 domains derived from GRB2 were used as adapters. The sensitivity and robustness of the RTK recruit-
ment assays were validated in dose-dependent inhibition assays using the ERBB family-selective antagonists lapatinib and 
WZ4002. The RTK split TEV recruitment assays also qualify for high-throughput screening approaches, suggesting that the 
artificial adapter may be used as universal adapter in cell-based profiling assays within pharmacological intervention studies.
Keywords Cell-based assay · Receptor tyrosine kinases · TEV protease · Split TEV recruitment assay · Lapatinib
Abbreviations
EGF  Epidermal growth factor
EGFld  EGF-like domain of NRG1
EGFR  Epidermal growth factor receptor
ERBB2  Erb-B2 receptor tyrosine kinase 2
ERBB3  Erb-B2 receptor tyrosine kinase 3
ERBB4  Erb-B2 receptor tyrosine kinase 4
GRB2  Growth factor receptor bound protein 2
HTS  High-throughput screening
IGF1R  Insulin growth factor 1 receptor
MET  Mesenchymal epithelial transition proto-onco-
gene, receptor tyrosine kinase
NRG1  Neuregulin 1
PIK3R1  Phosphoinositide-3-kinase regulatory subunit 1
RTK  Receptor tyrosine kinase
SHC1  Src homology 2 domain-containing adaptor 
protein 1
SH2  Src homology 2
TEV  Tobacco etch virus
Introduction
Receptor tyrosine kinases (RTKs) are type I transmem-
brane protein receptors and respond, with few exceptions, 
to extracellular cues. RTK-mediated signalling regulates key 
processes of cell biology, including intercellular commu-
nication, proliferation and differentiation, cell survival and 
metabolism, cell migration, and cell cycle control [1, 2]. 
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Further, RTK signalling is also implicated in central nervous 
system (CNS) and peripheral nervous system (PNS) devel-
opment [3]. RTKs share a similar architecture, which con-
sists of ligand-binding domains in the extracellular region, 
a single alpha-helix crossing the membrane and, in the cyto-
plasm, a juxtamembrane domain, a protein tyrosine kinase 
domain, and a carboxyl (C-) terminal regulatory region [2]. 
To date, 58 receptor tyrosine kinases in humans have been 
described, which can be divided into 20 subfamilies [2]. 
Together with the G protein-coupled receptors (GPCR), 
RTKs are the most important receptor class in human cells 
and represent the most relevant drug targets in the cell [4]. 
However, only 3% of marketed drugs target kinases as such, 
suggesting that the development of cell-based assays with 
broader applicability and robustness may contribute to bet-
ter medicines.
Upon ligand stimulation, RTKs dimerise that causes a 
kinase domain-mediated phosphorylation of the cytoplasmic 
receptor tails in trans, followed by phosphorylation-depend-
ent recruitment of adapter proteins. The ligand-induced 
binding between an RTK and an adapter is commonly medi-
ated by phosphotyrosine (p-Tyr) motifs, which are present in 
the cytoplasmic tail of an RTK and serve as docking sites for 
adapter proteins containing phospho-binding modules, such 
as the Src homology 2 (SH2) domain or phosphotyrosine-
binding (PTB) domain [5]. The SH2 domain is the largest 
class of p-Tyr recognition domains and comprises 120 dif-
ferent domains in 110 proteins [6]. The specificity of bind-
ing between a given SH2 domain and a p-Tyr docking site 
is mediated by the SH2 domain itself and the sequence of 
the p-Tyr motif, which is defined by the p-Tyr residue and 
its flanking residues [7].
One of the best studied RTK families is the Erb-b2 recep-
tor tyrosine kinases (ERBB) family comprising the epider-
mal growth factor (EGFR, also known as HER1 in humans) 
and ERBB2, ERBB3, and ERBB4 (also known as HER2, 
HER3, and HER4 in humans). The ERBB family has been 
linked to the development of, amongst other tissues, skin, 
heart, CNS, and PNS, and is widely implicated in human 
diseases, such as cancer and neurodevelopmental disorders 
including schizophrenia [2, 3]. Upon ligand stimulation, 
ERBB receptors homo- or heterodimerise, depending on the 
cellular context. ERBB2, however, is the preferred dimeri-
sation partner for the other ERBB receptors and does not 
respond to ligands [8, 9]. ERBB3 needs to heterodimerise 
to initiate downstream signalling, as the kinase domain lacks 
catalytic activity, and its preferred partner for heterodimeri-
sation is ERBB2 [10]. The major ligand for EGFR is the epi-
dermal growth factor (EGF), whereas ERBB3 and ERBB4 
are predominantly activated by neuregulins (NRG1-4) [11]. 
NRG binding to the receptor is mediated by the EGF-like 
domain (EGFld), which on its own can stimulate ERBB3 
and ERBB4 receptors [11].
The activity of ERBB receptors can be measured using 
genetically encoded bioassays, such as split TEV [12, 13]. 
This technique allows assessing dynamic protein–protein 
interactions in living cells and is based on the functional 
complementation of the tobacco etch virus (TEV) protease 
coupled to genetically encoded reporters, like the GAL4/
UAS system combined with firefly luciferase (Fluc) as 
reporter gene readout. The assay system was, for example, 
applied to monitor phosphorylation-dependent interactions 
of ERBB4 with the adapters PIK3R1 (regulatory subunit 
of PI3K), SHC1, and GRB2, as well as the EGFld-induced 
homodimer formation of ERBB4 and the heterodimer forma-
tion of ERBB2 and ERBB3 [13–16].
In this work, we describe the application of split TEV-
based RTK recruitment assays that provide a universal 
adapter recruitment strategy for robust and flexible cell-
based assays applicable to dose–response profiling and 
high-throughput screening (HTS) assays. To do this, dis-
ease-relevant RTKs such as the complete ERBB family, the 
insulin growth factor 1 receptor (IGF1R), and mesenchymal 
epithelial transition proto-oncogene (MET, also known as 
c-MET or hepatocyte growth factor receptor) were selected 
and tested in split TEV dose–response assays for their assay 
performance, both using endogenous full-length adapters 
and artificial adapters consisting of clustered SH2 domains. 
The latter ones were designed to increase flexibility, robust-
ness, and eventually lower the number of adapters needed 
for assaying various RTK activities, thus improving the com-
parability among the receptors tested. Notably, the artificial 
p-Tyr sensor based on the SH2 domain clustering derived 
from GRB2 displayed an improved signal-to-noise ratio in 
RTK recruitment assays. Furthermore, the p-Tyr sensor has 
been validated in dose–response assays using the ERBB 
family antagonists lapatinib and WZ4002, as well as the 
IGF1R inhibitor linsitinib and the MET antagonist foretinib. 
As expected, lapatinib and WZ4002 inhibited ERBB fam-
ily assays. However, challenging IGF1R and MET split 
TEV recruitment assays with lapatinib did not have an 
effect, demonstrating the sensitivity of our approach. Taken 
together, we established robust split TEV recruitment assays 
to sensitively monitor RTK receptor activities in living cells 
using a universal adapter protein as recruitment sensor.
Materials and methods
Plasmids
ORFs were PCR-amplified using the Pwo proofreading 
DNA Polymerase (Roche) and BP-recombined into the 
pDONR/Zeo plasmid using Gateway recombination clon-
ing (Life Technologies). Each entry vector was control 
digested using BsrGI, which releases the insert, and finally 
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verified by sequencing. LR recombination that was used 
to shuffle the ORFs from the entry vectors into the split 
TEV destination vectors (either pcDNA_attR1-ORF-attR2-
NTEV-tcs-GV-2xHA_DEST or pcDNA3_attR1-ORF-attR2-
CTEV-2xHA_DEST). The generation of the human ORFs 
for EGFR, ERBB2, ERBB3, ERBB4, SHC1, GRB2, and 
PIK3R1 has been described previously [16]. IGF1R and 
MET were obtained as pENTR plasmids from Harvard 
Plasmid ID (clone HsCD00040705) and Addgene (as part 
of the CCSB-Broad Human Kinase ORF Collection [17]), 
respectively. Concatenated ORFs of clustered SH2 domains 
that are flanked by attL1 and attL2 sites were synthesised 
by GenScript, USA. These sequences were provided in a 
pUC57 vector backbone harbouring a kanamycin resistance 
gene, allowing LR recombination cloning with destination 
vectors carrying an ampicillin resistance gene. DNA and 
protein sequences of clustered SH2 domains are provided 
in Fig. S1.
Cell culture
PC12 Tet-Off cells (Clontech, 631134, termed PC12 cells 
for simplicity) were maintained in DMEM medium (1 g/l 
glucose, Lonza) supplemented with 10% FCS, 5% horse 
serum (HS, Thermo Fisher Scientific), and 100 U/ml each of 
penicillin and streptomycin and 2 mM GlutaMAX. To starve 
PC12 cells, 2% FCS, 100 U/ml each of penicillin and strep-
tomycin and 2 mM GlutaMAX, but no HS, were added to the 
DMEM medium (1 g/l glucose). PC12 cells were grown on 
poly-L-lysine (Sigma) coated surfaces for maintenance and 
experiments. A549 cells (ATCC, CCL-185) were cultured 
in DMEM medium (4.5 g/l glucose) supplemented with 10% 
FCS and 100 U/ml each of penicillin and streptomycin and 
2 mM GlutaMAX. T-47D cells (ATCC, HTB-133) were 
cultured in RPMI 1640 medium supplemented with human 
insulin (f.c. 125 µg/l) (Sigma-Aldrich), 10% FCS, and 100 
U/ml each of penicillin and streptomycin and 2 mM Glu-
taMAX. Cells were cultured at 37 °C and 5%  CO2.
Biochemistry
For assessing the phosphorylation levels of EGFR, A549 
cells were starved overnight using 1% FCS, pre-incubated 
with increasing concentration of compounds [i.e. lapatinib 
(Selleckchem) or WZ4002 (Sigma-Aldrich)] at semi-loga-
rithmic scale for 1 h, and stimulated with 30 ng/ml EGF 
(Sigma-Aldrich) for 5 min. Likewise, T-47D were starved 
overnight using 0.5% FCS, pre-incubated with increasing 
concentration of compounds (i.e. lapatinib or WZ4002) at 
semi-logarithmic scale for 1 h, and stimulated with 10 ng/
ml EGF-like domain (Sigma-Aldrich) for 5 min. Split TEV 
expression plasmids were transfected into PC12 cells using 
Lipofectamine 2000 (Thermo Fisher Scientific) according to 
the manufacturer’s instructions. Cells were washed 1 × with 
PBS and lysed in a Triton-X lysis buffer (1% Triton-X100, 
50 mM Tris pH7.5, 150 mM NaCl, 1 mM EGTA) contain-
ing the Complete Protease Inhibitor Cocktail (Roche) and 
PhosSTOP phosphatase inhibitor (Roche). Briefly, cells 
were lysed and kept on ice for 10 min, sonicated 3 × for 
10 s at 4 °C, and denatured for 10 min at 70 °C. The Mini-
PROTEAN Tetra Electrophoresis System and Trans-Blot 
Turbo Blotting System (both Bio-Rad) were used for run-
ning and blotting protein gels. Chemiluminescence detection 
of proteins by Western blot analysis was performed using the 
Western LightningPlus-ECL kit (PerkinElmer). HA-tagged 
proteins were visualised using an HA antibody (clone 3F10, 
dilution 1:250, No. 11 867 423 001, Roche). The ERBB2-V5 
fusion was stained using a V5 antibody (clone D3H8Q, dilu-
tion 1:1000, Cell Signaling Technology). Phosphorylation 
levels of EGFR and ERBB4 were assayed using p-EGFR-
Y1068 (clone D7A5, dilution 1:500, No. 3777, Cell Sign-
aling Technology) and p-ERBB4-Y1284 antibodies (clone 
21A9, dilution 1:500, No. 4757, Cell Signaling Technology). 
Total EGFR and ERBB4 protein levels were determined 
using an anti-EGFR antibody (clone A-10, dilution 1:1000, 
sc-373746, Santa Cruz Biotechnology) and an anti-ERBB4 
antibody (clone E200, dilution 1:1000, ab32375, Abcam). 
Tubulin levels were determined using an anti-tubulin anti-
body (dilution 1:2000, No. T 5168, Sigma-Aldrich). For 
quantification, phosphorylation levels of p-EGFR relative 
to EGFR as well as p-ERBB4 relative to ERBB4 were cal-
culated using the Lukemiller protocol (http://lukem iller .org/
index .php/2010/11/analy zing-gels-and-weste rn-blots -with-
image -j/). Assays were run in triplicate.
Immunocytochemistry
On day 1, 1 Mio PC12 cells were plated on coverslips coated 
with poly-L-lysine (PLL) and placed in a six-well plate. On 
day 2, cells were transfected with EGFR-Glink-NTEV-tevS-
GV-2HA, ERBB2-var1-V5, ERBB3-Glink-NTEV-tevS-GV-
2HA, or ERBB4-JMa-CVT1-Glink-NTEV-tevS-GV-2HA 
using Lipofectamine 2000. On day 3, 50 µl of 1 × TBS was 
gently added per coverslip and removed twice to wash the 
cells, followed by fixation in 4% PFA diluted in 1 × TBS for 
10 min, washed again once in 1 × TBS and then permeabi-
lised in TBS/0.1% Triton X-100 for 5 min. Subsequently, 
cells were washed three times with 1 × TBS, then blocked 
in blocking buffer (3% BSA, 0.1% Triton X-100 in 1 × TBS) 
for 30 min at room temperature, and again washed three 
times with 1 × TBS. The HA antibody (Poly9023, BioLe-
gend) and the V5 antibody (clone D3H8Q, Cell Signaling 
Technology), respectively, were diluted in blocking buffer 
(1:1000) and added to the cells and incubated overnight at 
4 °C. After another three washing steps using 1 × TBS, the 
secondary antibody (Alexa 594 anti-rabbit, 1:500, Abcam, 
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ab150160) diluted in blocking buffer was added to the cells 
and incubated for 1 h at room temperature. Coverslips were 
washed three times in 1 × TBS, dipped into  ddH2O to remove 
traces of salt, mounted on microscope slides, and sealed with 
ProLong Gold Antifade Mountant with Dapi (ThermoFisher 
Scientific, P36935). Slides were imaged on a Zeiss Observer 
Z.1 microscope.
Split TEV recruitment end-point assays
Split TEV recruitment assays were run in six replicates per 
condition in 96-well plates. 50,000 PC12 cells per well were 
seeded onto poly-L-lysine (PLL)-coated plates. The next 
day, cells were transfected with assay plasmids using Lipo-
fectamine 2000. For transfection-based assays, no antibiotics 
were added to the medium. Per 96-well, a receptor-NTEV-
tcs-GV fusion plasmid (10 ng), an adapter-CTEV fusion 
plasmid for either SHC1 (10 ng), SH2(SHC1) (10 ng), 
SH2(GRB2) (10 ng), SH2(mix) (10 ng), PIK3R1(50 ng), 
SH2(PIK3R1) (50 ng), or GRB2 (2.5 ng), and an Fluc 
reporter plasmid (10  ng, Fluc driven by 10x clustered 
upstream activating sequences coupled to a minimal CMV 
promoter, 10 × UAS-minCMVp) were used. Addition-
ally, 1 ng of a plasmid constitutively expressing an EYFP 
that is fused to nuclear localisation sequence (EYFPnuc) 
driven by a CMV promoter was transfected per 96-well to 
assess transfection efficiencies (EYFPnuc). In detail, assay 
plasmids were diluted in 30 µl Opti-MEM (Thermo Fisher 
Scientific), vortexed, and mixed with 0.2 µl Lipofectamine 
2000 per well. The DNA/Lipofectamine/Opti-MEM mix 
was incubated for 20 min. The medium was removed from 
the wells and the DNA/Lipofectamine/Opti-MEM mix was 
added onto the cells. After 2 h of incubation, the mainte-
nance medium without antibiotics was added to the Opti-
MEM mix. On day 2, the maintenance medium was replaced 
by starvation medium. After 16–20 h (day 3), six wells per 
condition were stimulated with EGF (30 ng/ml, Sigma-
Aldrich), EGFld (10 ng/ml, Sigma-Aldrich), IGF1 (100 ng/
ml, PeproTech), and HGF (100 ng/ml, Sigma-Aldrich), while 
six wells were left non-stimulated. 16 h later (day 4), the 
medium was removed, and cells were lysed using Passive 
Lysis Buffer (Promega) and luciferase activity was analysed 
using a dual luciferase assay (Promega) in a Mithras LB 940 
Multimode Microplate Reader (Berthold Technologies). Sig-
nificance for assays was calculated using an unpaired t test 
in GraphPad Prism 5. Error bars are calculated as standard 
error of the mean (SEM).
For split TEV recruitment assays in a dose–response 
format, the following amendments to the general protocol 
were made. For a dose–response assay, all cells on the plate 
were transfected with the same receptor-NTEV-tcs-GV and 
adapter-CTEV fusions, the Fluc reporter plasmid, 1 ng of a 
plasmid constitutively expressing Renilla luciferase driven 
by a thymidine kinase promoter, and the EYFPnuc express-
ing plasmid. Renilla luciferase was used to assess toxic 
effects when applying compounds. For dose-dependent 
stimulation testing activation, six wells per condition were 
stimulated using increasing concentrations of an agonist at 
a semi-logarithmic scale. For assays testing inhibition, cells 
were treated with increasing concentrations of an antago-
nist at a semi-logarithmic scale, followed 1 h later by the 
addition of an agonist at a constant concentration. The fol-
lowing antagonists were used: lapatinib (Selleckchem), 
WZ4002 (Sigma-Aldrich), linsitinib (Selleckchem), and 
foretinib (Selleckchem). Dose–response data were analysed 
using the R-based ‘drc’ package, as described before [18, 
19]. Error bars are calculated as standard error of the mean 
(SEM). For ease of presentation and intuition, we have trans-
formed conventionally used  IC50 values into  pIC50 values 
[20]. These are calculated from  IC50 values using the for-
mula  pIC50 = − log10(IC50), with units of molar for  IC50 and 
therefore log(molar) for  pIC50.
Live cell split TEV recruitment assay
To identify an optimal time point of lysis for split TEV 
recruitment assays, firefly luciferase expression was con-
tinuously monitored using a 32-channel luminometer (lumi-
cycler 32 by ActiMetrics) for 69 h starting from the starva-
tion phase. For one assay, 1,000,000 PC12 cells were seeded 
on a 3.5 cm dish suitable for the instrument. The next day, 
100 ng of receptor-NTEV-tcs-GV, 100 ng of adapter-CTEV, 
and 100 ng of Fluc reporter plasmids were transfected using 
3.5 µl Lipofectamine 2000 and 1 ml Opti-MEM per dish. 
On day 2, cells were starved, and the cell culture medium 
was supplemented with 0.1% luciferin (Promega) to moni-
tor firefly luciferase activity in a live cell setup. The dishes 
were wrapped with parafilm to avoid excess evaporation of 
medium and put into the luminometer, which was placed 
inside a cell culture incubator set to 37 °C and 5%  CO2. All 
assays were run using three replicates per condition.
Results
Design of concatenated SH2 domains as universal 
adapter for split TEV recruitment assays
Split TEV assays are based on a TEV protease split into 
two inactive fragments, an N-terminal NTEV moiety and a 
C-terminal CTEV moiety. When assessing receptor activi-
ties, like for RTKs, the receptor is fused to the NTEV 
moiety, a TEV cleavage site (tcs), and the artificial co-acti-
vator GAL4-VP16 (GV), forming an NTEV-tcs-GV tag. 
Adapters are fused to CTEV (Fig. 1a). To establish RTK 
split TEV recruitment assays that use a universal adapter 
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and are sensitive, robust, and likely reduce interference 
with cellular signalling as compared to native adapters, 
we designed artificial adapter proteins that only consist 
of clustered SH2 domains. The SH2 domain sequences 
were taken from the human adapter proteins GRB2, SHC1, 
and PIK3R1 (Fig. 1b). Notably, these adapters are known 
to interact with various RTK subfamilies, including the 
ERBB family [2], the INSR family [21], and the HGFR 
family [22]. For the ERBB family, we had previously 
developed split TEV recruitment assays using full-length 
PIK3R1, GRB2, and SHC1 as adapter proteins [14]. By 
contrast, each artificial adapter protein was constructed to 
contain three concatenated SH2 domains (Fig. 1c, Fig. S1). 
For artificial GRB2 and SHC1 adapters, the single SH2 
domain present in the full protein was concatenated three 
times, termed SH2(GRB2) and SH2(SHC1). PIK3R1 con-
tains two SH2 domains, an N-terminal SH2 domain (SH2-
N), and a C-terminal SH2 domain (SH2-C). For the artifi-
cial adapter, two concatenated SH2-N domains were linked 
to a single SH2-C domain, termed SH2(PIK3R1). We also 
designed a chimeric protein adapter molecule containing 
one SH2 domain of each GRB2, SHC1, and the N-terminal 
SH2 domain of PIK3R1, termed SH2(mix). SH2 domains 
were separated via a flexible GS-linker formed of glycine, 
serine, and threonine residues (GGGGSTGGGGS) to 
allow for optimal folding and flexibility of binding.
The concatenated SH2(GRB2) domain is a universal 
adapter for RTK split TEV recruitment assays
For RTK split TEV recruitment assays, receptors were fused 
to the NTEV moiety along with tcs and GV, yielding RTK-
NTEV-tcs-GV fusion proteins. As receptors, we selected 
EGFR, ERBB3, and ERBB4 of the ERBB family, IGF1R 
of the INSR family and MET of the HGFR family. Adapter 
proteins were fused to the CTEV moiety. HTS-compatible 
split TEV recruitment assays are performed using an end-
point format (Fig. S2). Therefore, we first evaluated the 
optimal time point for this type of a split TEV assay. To 
do this, we monitored luciferase activity in a live cell split 
TEV recruitment assay using ERBB4 and PIK3R1, which 
has been used before in a compound screen [16]. ERBB4-
NTEV-tcs-GV was transfected together with PIK3R1-CTEV 
and the Fluc reporter into PC12 cells, which were starved 
to reduce baseline activity, and thus enable proper stimula-
tion by EGFld. The best stimulation to baseline ratio was 
obtained 16 h after stimulation (Fig. S3). Hence, all RTK 
split TEV recruitment assays using an end-point format were 
performed accordingly. To obtain a most sensitive adapter 
for RTK split TEV recruitment assays, we compared the per-
formance of established full-length adapters versus artificial 
domain adapters. First, we monitored the induced activity 









































Fig. 1  Design of a versatile split TEV recruitment assay for recep-
tor tyrosine kinases. a Scheme of the split TEV recruitment assay 
for receptor tyrosine kinases (RTKs). RTKs are fused to an NTEV 
moiety along with a TEV protease cleavage site (tcs) and an artifi-
cial co-transcriptional activator GAL4-VP16 (GV). Adapter proteins 
are fused to CTEV. Upon activation by a specific ligand (1), the RTK 
dimerises, is cross-phosphorylated by the kinase domains at Tyr resi-
dues, providing docking sites for adapter proteins that bind to phos-
phorylated tyrosines (2). The ligand-induced interaction between 
RTK and adapter causes the NTEV and CTEV moieties to form a 
reconstituted TEV protease (2). Reconstituted TEV protease cleaves 
at tcs to release GV (3). Liberated GV migrates to the nucleus and 
initiates expression of firefly luciferase (Fluc) (4). b Domain organi-
sation of full-length adapter proteins that are recruited by ERBB 
receptors. SH2 src homology 2 domain, SH3 src homology 3 domain, 
PID phosphotyrosine interaction domain, RHOGAP RhoGAP 
domain. Note that the adapter PIK3R1 contains two SH2 domains 
denoted as SH2-N (N-terminal) and SH2-C (C-terminal). c Domain 
organisation of the artificially concatenated SH2 domain phospho-
adapters. For each clustered SH2 adapter, three single SH2 domains 
were fused. The SH2(mix) adapter contains an SH2 domain taken 
from each full-length adapter depicted in (b)
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and ERBB4 using the three full-length adapters GRB2, 
SHC1, and PIK3R1, as well as the SH2 domain adapters 
SH2(GRB2), SH2(SHC1), SH2(PIK3R1), and SH2(mix) in 
PC12 cells (Fig. 2, Table S1). In these assays, EGFR activ-
ity was stimulated using EGF, whereas ERBB3 and ERBB4 
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using the SH2(GRB2) domain adapter scored highest for all 
ERBB receptor assays tested. Constitutive control Renilla 
luciferase readings remained stable for these assays (Fig. 
S4). In addition, various non-titrated amounts of transfected 
adapter plasmids that resulted in different expression lead 
to similar activation profiles of receptors, indicating that 
split TEV recruitment assays are robust and tolerate sub-
stantial differences in transfected adapter plasmids (Fig. S5). 
A live cell split TEV recruitment assay using ERBB4 and 
the SH2(GRB2) domain showed comparable kinetics to the 
ERBB4/PIK3R1 assay, indicating that the readout is stable 
over several hours (Fig. S3).
Then, we assessed whether RTK split TEV recruitment 
assays using full-length adapters and SH2 domain adapt-
ers can also be used to monitor the activity of RTKs that 
belong to other subfamilies. To do this, we selected IGF1R 
and MET that belong to INSR and HGFR families, respec-
tively. Indeed, activation of IGF1R (using the ligand IGF1) 
and MET (using the ligand HGF) was robustly monitored 
using the SH2(GRB2) domain adapter, suggesting that the 
artificial adapter formed of three SH2(GRB2) domains 
serves as a universal adapter in split TEV recruitment assays 
(Fig. 3, Fig. S4). A Western blot analysis validates that the 
RTK-NTEV-tcs-GV fusion proteins for EGFR, ERBB3, 
ERBB4, IGF1R and MET (each harbouring an HA tag at 
the C-terminus) and all adapter-CTEV fusion proteins (each 
also harbouring an HA tag at the C-terminus) were correctly 
expressed at expected sizes in PC12 cells (Figs. 2b, d, f, 3b, 
d, Table S2). For the ERBB3 split TEV recruitment assay, a 
non-TEV-tagged, but V5-tagged ERBB2 was co-transfected 
to enable ligand-induced phosphorylation of ERBB3, and 
successively, formation of p-Tyr docking sites (Fig. 2d). 
Using immunocytochemistry, the proper expression of the 
RTK-NTEV-tcs-GV fusions was corroborated, as all RTK 
fusion proteins were enriched at the cell surface in PC12 
cells (Fig. S6).
Next, we validated the sensitivity of RTK split TEV 
recruitment assays using the SH2(GRB2) adapter in agonist 
dose–response assays using increasing concentrations of the 
respective agonists (Fig. 4, Fig. S7). For ERBB recruitment 
assays, the SH2(SHC1) and SH2(mix) adapters showed, 
compared to the SH2(GRB2) adapter, lower signal-to-noise 
ratios and reduced sensitivity in dose–response assays 
(Fig. 4a–c, Figs. S7, S8). Notably, agonist dose–response 
split TEV recruitment assays for both IGF1R and MET and 
applying the SH2(GRB2) adapter also resulted in robust 
dose-dependent increases of receptor activity (Fig. 4d, e, 
Fig. S7). Taken together, we identified the three times con-
catenated SH2 domain of GRB2, termed SH2(GRB2), as 
universal adapter for our set of selected RTK receptor split 
TEV recruitment assays.
The SH2(GRB2) universal adapter efficiently 
monitors lapatinib inhibition across all ERBB family 
receptors
Cell-based assays are frequently used to assess a com-
pound’s potential to inhibit the activity of a given recep-
tor, such as for an RTK [23]. To measure the impact of 
inhibitory compounds on RTK targets using our split TEV 
recruitment assays, we challenged them with the well-char-
acterised pan-ERBB family inhibitor lapatinib that is used 
in the clinic [24] and determined  IC50 values for each assay 
(Fig. 5a–f, Figs. S9, S10). For a more intuitive compari-
son among assays, we transformed  IC50 values into  pIC50 
values reflecting a logarithmic scale (see “Materials and 
methods” for details) (Fig. 5f, Table S3). When compared 
across ERBB receptor assays using both full-length and 
SH2 domain adapters, split TEV recruitment assays using 
the universal adapter SH2(GRB2) are most sensitive to 
lapatinib inhibition (Fig. 5f). The constitutive Renilla lucif-
erase readout enabled us to discriminate between inhibi-
tory and toxic effects, with the latter ones only occurring at 
30 µM lapatinib (Fig. S9). We found in our assays using the 
SH2(GRB2) adapter that lapatinib efficiently inhibits EGFR 
 (IC50: 305 nM,  pIC50: 6.52) and ERBB2/ERBB3  (IC50: 
72 nM,  pIC50: 7.14), and ERBB4  (IC50: 166 nM,  pIC50: 
6.78). However, lapatinib treatment did not inhibit IGF1R 
and MET activities (Fig. 5d, e, Fig. S9). In concordance with 
the literature, stimulated IGF1R and MET receptors were 
efficiently inhibited by linsitinib and foretinib, respectively 
(Fig. S9) [25, 26]. To further compare the sensitivity of our 
split TEV RTK recruitment assays with cellular assays that 
Fig. 2  Comparing adapter protein performance for split TEV recruit-
ment assays to monitoring ERBB receptor activities. Split TEV 
recruitment assays for ERBB family receptors. EGFR (a), ERBB2/
ERBB3 (c), and ERBB4 (e) activities were assessed in PC12 cells 
using EGF to stimulate EGFR, and EGF-like domain (EGFld) to 
stimulate ERBB3 and ERBB4. For split TEV assays, the indicated 
receptor fusions were transfected together with indicated adapters that 
were fused to the CTEV moiety. Note that for the ERBB2/ERBB3 
assay (c), ERBB2 is co-transfected to allow heterodimerisation and 
thus ERBB3 phosphorylation, which is required for the recruitment 
of adapters. Assays were stimulated for 16 h and analysed by a fire-
fly luciferase assay. Non-stimulated samples are shown as open bars 
and stimulated ones as grey bars. FC fold change, Ctrl control (no 
adapter transfected). Results are shown as average of six samples, and 
error bars are shown as SEM. Significance was calculated using the 
unpaired t test, with **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001; n.s. 
not significant. Precise p values are provided in Table S1. Biochemi-
cal validation of the expression of ERBB receptors and adapters. 
Plasmids encoding EGFR (b), ERBB3 (d), and ERBB4 (f) (all tagged 
with NTEV-tcs-GV-2HA), ERBB2-V5 (d), and adapter proteins (all 
tagged with CTEV-2HA) were transiently transfected into PC12 cells, 
allowed to express for 16  h, and lysed. Lysates were subjected to 
Western blotting using the indicated antibodies. Calculated sizes of 
fusion proteins are provided in Table  S1. Arrow indicates bands of 
artificial adapter fusions. Note that SH2(PIK3R1) is only very weakly 
expressed
◂
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use phospho-specific antibodies to monitor RTK activity, 
we explored the potency of EGFR and ERBB4 inhibition by 
lapatinib by assessing the phosphorylation levels of EGFR in 
A549 cells and of ERBB4 in T-47D cells. Both cell lines are 
of human origin and reasonably express EGFR and ERBB4, 
respectively. Dose-dependent addition of lapatinib led to an 
efficient inhibition of p-EGFR and p-ERBB4, as revealed by 
Western blotting (Fig. 5g–j, Fig. S11). Quantification of our 
Western blotting data indicate that EGFR and ERBB4 are 
inhibited by lapatinib at similar concentrations in cellular 
assays when comparing antibody-based detection of phos-
phorylation levels and split TEV-based RTK recruitment 
assays. By contrast, a biochemical kinome profiling study 
reported that both EGFR (2.4 nM, kD) and ERBB2 (7 nM, 
kD) are more potently inhibited than ERBB4 (54 nM, kD) 
[27]. In support of our findings, data from published cellular 
assays, which use lysates as input for enzyme-linked immu-
nosorbent assays (ELISA) and applied phospho-specific 






















































































































































































Fig. 3  Comparing adapter protein performance for split TEV recruit-
ment assays to monitoring IGF1R and MET receptor activities. a, c 
Split TEV recruitment assays for IGF1R and MET receptors. IGF1R 
(a) and MET (c) activities were assessed in PC12 cells using IGF1 
to stimulate IGF1R, and HGF to stimulate MET. For split TEV 
assays, the indicated receptor fusions were transfected together with 
indicated adapters that were fused to the CTEV moiety. Assays were 
stimulated for 16  h and analysed by a firefly luciferase assay. Non-
stimulated samples are shown as open bars and stimulated ones 
as grey bars. FC fold change, Ctrl control (no adapter transfected). 
Results are shown as average of six samples, error bars are shown 
as SEM. Significance was calculated using the unpaired t test, with 
**p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001; n.s. not significant. Pre-
cise p values are provided in Table S1. b, d Biochemical validation 
of the expression of IGF1R and MET receptors and adapters. Plas-
mids encoding IGFR1 (b), and MET (d) (all tagged with NTEV-tcs-
GV-2HA) and adapter proteins (all tagged with CTEV-2HA) were 
transiently transfected into PC12 cells, allowed to express for 16  h, 
and lysed. Lysates were subjected to Western blotting using the indi-
cated antibodies. Calculated sizes of fusion proteins are provided in 
Table  S1. Arrow indicates bands of artificial adapter fusions. Note 
that SH2(PIK3R1) is only very weakly expressed. Arrowhead indi-
cates band for MET, which is also very weakly expressed
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antibodies as sensor of receptor activity, reported a simi-
lar range of concentrations for  IC50 values of EGFR and 
ERBB2 inhibition, suggesting that efficiencies may sub-
stantially vary between biochemical and cell-based assays 
(Table 1, Table S4) [24, 27–29]. Taken together, our own 
data obtained from the split TEV recruitment assays indi-
cate that lapatinib efficiently inhibits ERBB receptors, with 
preferentially inhibiting ERBB2/ERBB3 (72 nM,  IC50) and 
ERBB4 (166 nM,  IC50) over EGFR (305 nM,  IC50). 
To corroborate the use of our cell-based assays using 
the split TEV recruitment technique and the SH2(GRB2) 
adapter, we also tested the pan-ERBB inhibitor WZ4002 
(Table 1, Table S5) [30, 31]. By performing antagonistic 
dose–response assays for WZ4002, we could confirm the 
usage of SH2(GRB2) as a universal adapter in ERBB split 
TEV recruitment assays. In split TEV assays, WZ4002 effi-
ciently inhibited ERBB family receptors EGFR, ERBB3, and 
ERBB4 (Fig. 6a–c). Dose-dependent addition of WZ4002 
to A549 and T-47D cells reduced phospho-levels of EGFR 
and ERBB4 to similar levels when compared to split TEV 
recruitment assays, as quantification of phospho-EGFR and 
phospho-ERBB4 indicates (Fig. 6d–g, Fig. S11). Further, we 
tested whether spironolactone exerts antagonistic effects on 
ERBB family receptors as recently reported [16]. Spirono-
lactone is a pan-ERBB inhibitor, displaying selectivity for 
ERBB4 over EGFR, as previously determined using a split 
TEV dimerisation assay. Spironolactone also inhibited 
ERBB activities using the universal SH2(GRB2) adapter in 
the split TEV recruitment assays, with some selectivity for 
ERBB4 over EGFR (Fig. S12). Further, the spironolactone 
metabolite canrenone did not exhibit any antagonistic effects 
on any ERBB assay, which is also consistent with our previ-
ous findings [16] (Fig. S12). In summary, these data sug-
gest that the adapter SH2(GRB2) can be used in split TEV 
recruitment assays to monitor both agonist and antagonist 
actions targeting the RTK ERBB family in living cells.
Discussion
We describe a genetically encoded split TEV recruitment 
assay to monitor RTK activities using a universal adapter 
that consists of three concatenated SH2 domains, which 
bind to phosphorylated tyrosine residues. As examples for 
RTKs, we have selected the ERBB receptor family, IGF1R 
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Fig. 4  The concatenated SH2(GRB2) domain fusion is a univer-
sal adapter to profile ERBB, IGF1R, and MET activities. Split TEV 
recruitment assays using increasing concentrations of agonists (EGF, 
EGFld, IGF1 and HGF shown below x axis) for the receptors EGFR 
(a), ERBB2/ERBB3 (b), ERBB4 (c), IGF1R (d), and MET (e). Each 
receptor fusion (NTEV-tcs-GV tag for EGFR, ERBB3, ERBB4, 
IGF1R, MET; V5-tagged ERBB2) plasmid was co-transfected with 
the SH2(GRB2)-CTEV adapter plasmid into PC12 cells. Error bars 
are shown as SEM, with six replicates per condition
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full-length adapters GRB2, SHC1, and PIK3R1, as well as 
artificially constructed adapters consisting of concatenated 
SH2 domains of GRB2, SHC1, and PIK3R1 for efficient 
assay performance upon RTK receptor stimulation (Fig. 1). 
The adapter formed of three concatenated SH2 domains 
of GRB2, SH2(GRB2) displayed the best signal-to-noise 
ratio across all RTK biosensor assays tested (Figs. 2, 3), 
and the performance of this adapter was further validated in 
dose–response assays (Fig. 4). In addition, the SH2(GRB2) 
adapter was characterised in antagonist dose–response 
assays by applying the ERBB family inhibitors lapatinib, 
WZ4002, and spironolactone (Figs. 5, 6, Fig. S12).
SH2(GRB2) as a universal adapter for RTK activity 
measurement
For integrating cell-based assays into HTS, an appropriate 
signal-to-noise ratio is key to robustness [23, 32]. Therefore, 
the SH2(GRB2) adapter represents a universal approach 
towards HTS assays. In agreement, the SH2 domain of 
GRB2 was reported to bind all members of the ERBB fam-
ily in a biochemical study using protein microarrays, sup-
porting our findings of SH2(GRB2) as universal adapter 
[33]. The SH2 domain of GRB2 was also applied as p-Tyr 
sensor in living cells, where the SH2 domain was fused to 
the photoactivatable fluorescent protein tdEos to monitor 
EGFR activation [34]. Furthermore, full-length GRB2 has 
been shown to stronger bind to p-Tyr motifs present in EGFR 
and ERBB4 when compared to SHC1, suggesting that the 
SH2 domain of GRB2 is a better fit for a universal adapter 
in split TEV recruitment assays [35]. The general consensus 
sequence of the p-Tyr motifs that the SH2 domain of GRB2 
binds to was initially described as pY-X-N [36]. However, 
a more recent study expanded this view to a more general 
consensus sequence pY-[ϕ/Q]-[NQFDK], where ϕ stands for 
a hydrophobic residue [35], supporting the notion that the 
SH2 domain of GRB2 can bind to p-Tyr motifs with a rather 
flexible sequence. As the SH2 domain adapter only consists 
of SH2 domains and no other interaction modules are pre-
sent in this adapter, this artificial adapter may solely func-
tion as a p-Tyr sensor [37]. Furthermore, the SH2(GRB2) 
adapter may be used for monitoring activities of other RTKs, 
such as the insulin growth factor receptor and tropomyosin 
receptor kinase families that also bind GRB2, potentially 
expanding the number of receptors [38, 39]. The split TEV 
recruitment assays presented are based on transient trans-
fections and thus use overexpressed receptors and adapters. 
Therefore, we would like to emphasise that RTK split TEV 
recruitment assays were specifically designed to assay recep-
tor activities in heterologous cells, and these assays may 
not be combined with analyses of downstream signalling 
[40]. As heterologous cells display abnormal activities of 
downstream signalling, events of cellular signalling should 
preferably be monitored in primary cell types. By contrast, 
activities of receptors may well be studied in heterologous 
cell lines, as studying receptor activities implicates the first 
step of a signalling cascade [23].
When RTKs become activated, the phosphorylation 
of intracellular tyrosine residues represents the first step 
upon ligand binding. Notably, different agonist ligands 
and varying concentrations thereof may cause diverse 
cellular outcomes, as for example described for EGFR 
ligands that differentially affect EGFR endocytosis and 
recycling [41]. Thus, it is of common interest to specify 
which of these tyrosine residues of an RTK are phos-
phorylated and act as docking sites for adapter proteins 
to initiate signalling [42]. Alternatively, phosphorylated 
docking sites may act additively to elicit a response by 
recruiting a defined set of adapters [43]. To understand 
which phospho-signature is generated by a given RTK, 
e.g. after agonist or antagonist treatment, full-length 
adapters as well as SH2 domain adapters may be used 
for profiling of biased adapter recruitment. In our split 
TEV recruitment assays, EGFR activation, for example, 
can be detected at very low EGF concentrations using 
the GRB2 full-length protein as adapter (Fig. S8). By 
contrast, when treating ERBB3 with the antagonist lapa-
tinib, full-length PIK3R1 proved to be the most sensitive 
adapter protein to measure an inhibition (Fig. 5f, Fig. 
S10). The adapter SH2(GRB2) does not cover aspects 
of biased signalling per se, but can be used as universal 
adapter to study RTK activity profiles. Assessing differ-
ential binding properties may be important, as adapters 
have varying binding affinities to activated receptors and 
binding affinities depend on ligand concentrations [44]. 
Likewise, receptors can recruit distinct sets of adapter 
Fig. 5  The universal SH2(GRB2) adapter displays the highest sen-
sitivity to ERBB family inhibition by lapatinib. Split TEV recruit-
ment assays monitoring the lapatinib-mediated inhibition of EGFR 
(a), ERBB2/ERBB3 (b), ERBB4 (c), IGF1R (d), and MET (e). Each 
receptor fusion (NTEV-tcs-GV tag for EGFR, ERBB3, ERBB4, 
IGF1R, MET; V5-tagged ERBB2) plasmid is co-transfected with 
the universal SH2(GRB2)-CTEV adapter plasmid into PC12 cells. 
Depicted are dose–response curves with a constant agonist stimu-
lus (EGF, EGFld, IGF1, and HGF) and increasing concentrations of 
lapatinib. Error bars are shown as SEM, with six replicates per condi-
tion. f Heatmap displaying  pIC50 values for lapatinib comparing assay 
performance of full-length and SH2(GRB2) domain concatenated 
CTEV adapters co-transfected with the ERBB family NTEV-tcs-GV 
fusions. Lapatinib reduces p-EGFR (Y1068) levels in A549 cells (g, 
h) and p-ERBB4 (Y1284) in T-47D cells (i, j). Cells were treated 
for 1 h with increasing concentrations of lapatinib and stimulated for 
5 min with 30 ng/ml EGF (g) or 10 ng/ml EGFld (i) where indicated. 
Lysates were subjected to Western blotting and probed with indicated 
antibodies. Quantification of p-EGFR/EGFR levels (h) as shown in 
(g) and p-ERBB4/ERBB4 levels (j) as shown in (i) are plotted as 
dose–response curves. For each concentration depicted, three data 
points from three different lysates were used for calculations (c.f. Fig. 
S11a, b)
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proteins to initiate specific downstream signalling [45]. 
Thus, the SH2(GRB2) adapter may be used for a primary 
assessment of RTK activity in recruitment assays, fol-
lowed by more specialised assays (e.g. using other adap-
tors in split TEV recruitment assays or cell-based assays 
using phospho-antibodies) to determine signalling fate.
In addition, usage of the universal adapter is not 
restricted to split TEV-based recruitment assays, but can 
be implemented into all genetically encoded recruitment 
assays that, for example, rely on the complementation of 
a reporter protein, the release of an artificial transcrip-
tion factor, or both. For example, split green fluorescent 
protein (GFP) assays (and derivatives) [46, 47], split 
firefly luciferase [48], split ubiquitin [49], and full-TEV 
protease assays [50] may be applicable. Furthermore, the 
SH2(GRB2) adapter may also be used in fluorescence 
resonance energy transfer (FRET) and bioluminescence 
resonance energy transfer (BRET)-based assays [51, 52]. 
Taken together, the universal SH2(GRB2) adapter repre-
sents a p-Tyr biosensor to monitor RTK activities and may 
be used in various cell-based assays that are genetically 
encoded.
Lapatinib preferentially inhibits ERBB4 over EGFR 
in RTK/SH2 adapter recruitment assays
Lapatinib, an EGFR and ERBB2 receptor inhibitor, is used 
in the clinics, e.g. in combination therapies to treat cancers 
[53, 54]. It has been shown that lapatinib also inhibits 
ERBB3 and ERBB4 receptors in biochemical profiling 
studies [27]. Compared to data obtained from biochemi-
cal assays,  IC50 concentrations for lapatinib were substan-
tially higher in cell-based assays [24, 27, 28] (Table 1, 
Table S4), suggesting that efficiencies of compounds in 
living cells cannot be precisely predicted from biochemi-
cal data. Thus, compounds should be efficiently tested in 
cell-based assays that best reflect the nature or the tar-
get or, in the case of a disease-linked phenotype, most 
faithfully replicate the disease state [23]. Furthermore, 
antagonistic preferences of a given target over related tar-
gets, a feature important for characterising selectivity of a 
compound, may vary between biochemical and cell-based 
assays, supporting the notion of applying the most appro-
priate test system possible.
Table 1  IC50 and  KD values for ERBB receptor family inhibition by lapatinib and WZ4002 in cellular and biochemical assays
ELISA and Western blotting data were retrieved from the PubChem database (https ://pubch em.ncbi.nlm.nih.gov) and indicated references. Note 
that ELISA and Western blotting data from these sources were obtained using phospho-specific antibodies and cellular lysates. The full data set 
comprising both biochemical and cellular assays are shown in Table S4 (lapatinib) and Table S5 (WZ4002)
n.a. not applicable
Name of compound Compound ID (CID) Target PubChem 
assay ID 
(AID)
Type of assay IC50 (nM)/KD pIC50 References
Lapatinib 208908 EGFR 474116 ELISA, cellular lysates 52 7.28 [28]
Lapatinib 208908 EGFR 517323 ELISA, cellular lysates 433 6.36 [29]
Lapatinib 208908 EGFR n.a. Split TEV, cell-based assay 305 6.52 This study
Lapatinib 208908 EGFR 624996 Biochemical 2.4 8.62 [27]
Lapatinib 208908 ERBB2 474117 ELISA, cellular lysates 100 7.00 [28]
Lapatinib 208908 ERBB2 517324 ELISA, cellular lysates 140 6.85 [29]
Lapatinib 208908 ERBB2/ERBB3 n.a. Split TEV, cell-based assay 72 7.14 This study
Lapatinib 208908 ERBB2 624804 Biochemical 7 8.15 [27]
Lapatinib 208908 ERBB3 624851 Biochemical 5500 5.26 [27]
Lapatinib 208908 ERBB4 n.a. Split TEV, cell-based assay 166 6.78 This study
Lapatinib 208908 ERBB4 624815 Biochemical 54 7.27 [27]
WZ4002 44607530 EGFR 770081 Western blotting, cellular 
lysates
1180 5.93 [30]
WZ4002 44607530 EGFR n.a. Split TEV, cell-based assay 4019 5.40 This study
WZ4002 44607530 EGFR 1204628 Biochemical 16 7.79 [55]
WZ4002 44607530 ERBB2/ERBB3 n.a. Split TEV, cell-based assay 215 6.67 This study
WZ4002 44607530 ERBB2 1204629 Biochemical 0.42 9.37 [55]
WZ4002 44607530 ERBB3 1204629 Biochemical 0.42 9.37 [55]
WZ4002 44607530 ERBB4 n.a. Split TEV, cell-based assay 1007 6.00 This study
WZ4002 44607530 ERBB4 1204629 Biochemical 0.42 9.37 [55]
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Profiling multiple RTK activities simultaneously 
using multiplexed cell-based assays
The abnormal activities of RTKs are linked to the 
pathophysiology of various human diseases, such as cancers, 
diabetes, inflammation, angiogenesis, neurodegenerative dis-
eases, and psychiatric disorders [2, 3]. Therefore, these asso-
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Fig. 6  The ERBB family antagonist WZ4002 inhibits split TEV 
recruitment assays using the universal SH2(GRB2) adapter. Split 
TEV recruitment assays monitoring the WZ4002-mediated inhibi-
tion of EGFR (a), ERBB2/ERBB3 (b), and ERBB4 (c). Each recep-
tor fusion (NTEV-tcs-GV tag for EGFR, ERBB3, ERBB4; V5-tagged 
ERBB2) plasmid is co-transfected with the universal SH2(GRB2) 
CTEV adapter into PC12 cells. Depicted are dose–response curves 
with a constant stimulus (EGF, EGFld) and increasing concentra-
tions of lapatinib. Error bars are shown as SEM, with six replicates 
per condition. WZ4002 reduces p-EGFR (Y1068) levels in A549 
cells (d, e) and p-ERBB4 (Y1284) in T-47D cells (f, g). Cells were 
treated for 1 h with increasing concentrations of WZ4002 and stimu-
lated for 5 min with 30 ng/ml EGF (d) or 10 ng/ml EGFld (f) where 
indicated. Lysates were subjected to Western blotting and probed 
with the indicated antibodies. Quantification of p-EGFR/EGFR levels 
(e) as shown in (d) and p-ERBB4/ERBB4 levels (g) as shown in (f) 
are plotted as dose–response curves. For each concentration depicted, 
three data points from three different lysates were used for calcula-
tions (c.f. Fig. S11c, d)
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attenuate aberrant activity of RTKs. However, many availa-
ble drugs targeting RTKs lack selectivity, demonstrating the 
medical need for the development of better drugs. The need 
for more specific drugs is also reflected by the fact that only 
3% of all marketed drugs target kinases including RTKs [4]. 
Cell-based profiling techniques that enable the simultaneous 
analysis of multiple targets and allow defining selectivity of 
a given compound will contribute to the development of bet-
ter drugs [12]. For example, multiplexed cell-based assays 
that rely on complementation of a reporter, the release of an 
artificial transcription factor, and the use of barcoded RNA 
sequences as reporters can be applied to profile activities of 
disease-relevant targets, as we have recently shown for G 
protein-coupled receptors (GPCRs) [40]. Therefore, using 
the split TEV recruitment assay and integrating the universal 
SH2(GRB2) adapter may represent a promising approach to 
build a technology platform to assess RTK activities in early 
drug discovery to finally improve compound selectivity.
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Fig. S1 continued 
 













































Fig. S1. DNA and protein sequences of concatenated SH2 domain adapters.  
SH2 domains are highlighted in cyan (for DNA sequences) and green (for protein sequences). SH2 
domains are spaced by flexible linkers (with protein sequence GGGGSTGGGGS). (a) Three 
concatenated SH2 domains of human GRB2; denoted as SH2(GRB2). (b) Three concatenated SH2 
domains of human SHC1; denoted as SH2(SHC1). (c) Three concatenated SH2 domains of human 
PIK3R1, using twice the N-terminal SH2 domain (SH2-N) of PIK3R1, and once the C-terminal SH2 
domain (SH2-C) of PIK3R1; denoted as SH2(PIK3R1). (d) Three concatenated SH2 domains of human 











Fig. S3. Split TEV ERBB4 recruitment assays optimally respond after 16 h of stimulation. 
The ERBB4-NTEV-tcs-GV (ERBB4) receptor plasmid was transfected into PC12 cells together with a 
firefly luciferase (Fluc) reporter plasmid, and either a plasmid encoding the full-length adapter 
PIK3R1-CTEV (assay: ERBB4/PIK3R1) (a) or the SH2-domain adapter SH2(GRB2)-CTEV (assay: 
ERBB4/SH2(GRB2) (b). Luciferase activity was measured every 10 minutes. Time point at 0 h denotes 
the start of the stimulation phase at which 10 ng/mL EGF-like domain (EGFld) were added to the 
medium. The dashed line at 16 h represents the highest ratio of stimulation to baseline activity. An 




Fig. S4. Constitutive Renilla luciferase readings are stable in growth factor stimulated RTK split TEV 
recruitment assays. 
Thymidine kinase-driven Renilla luciferase signals were assessed in EGFR (a), ERBB2/ERBB3 (b), 
ERBB4 (c), IGF1R (d), and MET (e) split TEV recruitment assays under control and stimulated 
conditions in PC12 cells. EGF was applied to stimulate EGFR, EGF-like domain (EGFld) to stimulate 
ERBB3 and ERBB4, IGF1 to stimulate IGF1R and HGF to stimulate MET. The indicated receptor fusions 
were transfected together with indicated adapters that were fused to the CTEV moiety. Note that for 
the ERBB2/ERBB3 assay (b), ERBB2 is co-transfected to allow heterodimerisation and thus ERBB3 
phosphorylation, which is required for the recruitment of adapters. Assays were stimulated for 16 h, 
lysed and analysed for Renilla activity. Non-stimulated samples are shown as open bars and 
stimulated once as grey bars. Error bars represent SD, with 6 replicates per condition. Fig. S5 









Fig. S5. Transient RTK split TEV recruitment assays tolerate differences in transfected adapter 
plasmids. 
a–f Split TEV recruitment assays for EGFR (a, b), ERBB2/ERBB3 (c, d), and ERBB4 (e, f). Note that for 
the ERBB2/ERBB3 assay (c), ERBB2 is co-transfected to allow heterodimerisation and thus ERBB3 
phosphorylation, which is required for the recruitment of adapters. Assays were stimulated for 16 h, 
and analysed by a firefly luciferase assay. Non-stimulated samples are shown as open bars and 
stimulated once as grey bars. Ctrl, control (no adapter transfected). Non-stimulated samples are 
shown as open bars and stimulated once as grey bars. FC, fold change; Ctrl, control (no adapter 
transfected). Results are shown as average of 6 samples, error bars are shown as SEM. Significance 
was calculated using the unpaired t-test, with **, p≤0.01; ***, p≤0.001; ****, p≤0.0001; n.s. not 
significant.  
g, h Biochemical validation of the expression of titrated (g) vs. non-titrated (h) adapters. Plasmids 
encoding adapter proteins (all tagged with CTEV-2HA) were transiently transfected into PC12 cells, 
allowed to express for 16 h, and lysed. Lysates were subjected to Western blotting using the 
indicated antibodies. Note that PIK3R1 is very low expressed in (g), whereas GRB2 is strongly 
expressed in (h). SH2(PIK3R1) is below detection limit in (h). Calculated sizes of fusion proteins are 





Fig. S6. RTK split TEV fusions are expressed at the cell membrane in PC12 cells. 
RTK fusions are expressed at the cell membrane. Plasmids encoding EGFR, ERBB3, ERBB4, IGF1R, and 
MET (all tagged with NTEV-tcs-GV-2HA), ERBB2-V5, and adapter proteins (all tagged with CTEV-2HA) 
were transiently transfected into PC12 cells and fixed 20 h later for immunocytochemistry stainings. 
Receptor expression is displayed for EGFR-, ERBB3-, ERBB4-, IGF1R-, and MET-NTEV-tcs-GV-2HA (red, 
HA staining) as well as for ERBB2-V5 (red, V5 staining). Nuclei are displayed in blue (Dapi staining). 





Fig. S7. Constitutive Renilla luciferase readout is stable at increasing ligand concentrations. 
Split TEV recruitment assays monitoring the activity of EGFR (a), ERBB2/ERBB3 (b), ERBB4 (c), IGF1R 
(d), and MET (e). Each receptor fusion (NTEV-tcs-GV tag for EGFR, ERBB3, ERRB4, IGF1R, and MET; 
V5-tagged ERBB2) plasmid is co-transfected with the universal SH2(GRB2) CTEV adapter plasmid into 
PC12 cells. Depicted are dose–response curves, with agonists applied at increasing concentrations as 
indicated (EGF, EGFld, IGF1, HGF). Firefly luciferase is shown in black (as in Fig. 4), the constitutive 








Fig. S8. Agonist dose–response data of split TEV recruitment assays for EGFR, ERBB2/ERBB3, and 
ERRB4 using full length and concatenated SH2 domain adapters. 
EGFR (a–e), ERBB2/ERBB3 (f–j) and ERBB4 (k–o) split TEV recruitment assays were performed as 
dose–response assays in PC12 cells using full-length adapters of GRB2 (a, f, k), SHC1 (b, g, l), PIK3R1 
(c, h, m), as well as SH2 domain adapters SH2(SHC1) (d, i, n) and SH2(mix) (e, j, o). Agonists EGF and 
EGF-like domain (EGFld) were applied at increasing concentrations as indicated. For each assay, 
plasmids encoding a receptor and an adapter, were co-transfected with a 10xUAS-minCMVp-driven 
firefly luciferase (Fluc) reporter plasmid shown in black and the constitutive Renilla luciferase is 
shown in grey, as follows: 
(a) EGFR-NTEV-tcs-GV, GRB2-CTEV 
(b) EGFR-NTEV-tcs-GV, SHC1-CTEV 
(c) EGFR-NTEV-tcs-GV, PIK3R1-CTEV 
(d) EGFR-NTEV-tcs-GV, SH2(SHC1)-CTEV 
(e) EGFR-NTEV-tcs-GV, SH2(mix)-CTEV 
(f) ERBB3-NTEV-tcs-GV, ERBB2, GRB2-CTEV 
(g) ERBB3-NTEV-tcs-GV, ERBB2, SHC1-CTEV 
(h) ERBB3-NTEV-tcs-GV, ERBB2, PIK3R1-CTEV 
(i) ERBB3-NTEV-tcs-GV, ERBB2, SH2(SHC1)-CTEV 
(j) ERBB3-NTEV-tcs-GV, ERBB2, SH2(mix)-CTEV 
(k) ERBB4-NTEV-tcs-GV, GRB2-CTEV 
(l) ERBB4-NTEV-tcs-GV, SHC1-CTEV 
(m) ERBB4-NTEV-tcs-GV, PIK3R1-CTEV 
(n) ERBB4-NTEV-tcs-GV, SH2(SHC1)-CTEV 
(o) ERBB4-NTEV-tcs-GV, SH2(mix)-CTEV 





Fig. S9. Antagonists lapatinib, linsitinib and foretinib inhibit their cognate RTK targets. 
a–d Split TEV recruitment assays monitoring the lapatinib-mediated inhibition of EGFR (a), 
ERBB2/ERBB3 (b), and ERBB4 (c), but not IGFR1 (d) nor MET (e). f, g Linsitinib-mediated inhibition of 
IGF1R (d), and foretinib-mediated inhibition of MET (e). Each receptor fusion (NTEV-tcs-GV tag for 
EGFR, ERBB3, ERRB4, IGF1R, and MET; V5-tagged ERBB2) plasmid is co-transfected with the universal 
SH2(GRB2)-CTEV adapter plasmid into PC12 cells as indicated. Depicted are dose–response curves 
with a constant agonist (EGF, EGFld, IGF1, HGF) and increasing concentrations of lapatinib (a–d), 
linsitinib (e) and foretinib (g). Firefly luciferase is shown in black (as in Fig. 5), the constitutive Renilla 
luciferase is shown in grey. Note that the constitutive Renilla luciferase readout indicates toxicity of 






Fig. S10. Dose–response data of ERBB family split TEV recruitment assays using full length and 
concatenated SH2 domain adapters testing lapatinib inhibition. 
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EGFR (a–d), ERBB2/ERBB3 (e–h) and ERBB4 (i–l) split TEV recruitment assays were performed as 
dose–response assays in PC12 cells using full-length adapters of GRB2 (a, e, i), SHC1 (b, f, j), PIK3R1 
(c, g, k), and the SH2 domain adapter SH2(SHC1) (d, h, l). The ERBB family antagonist lapatinib was 
applied at increasing concentrations as indicated. Agonists EGF and EGF-like domain (EGFld) were 
applied at constant concentrations as indicated. For each assay, plasmids encoding a receptor and an 
adapter, were co-transfected with a 10xUAS-minCMVp-driven firefly luciferase (Fluc) reporter 
plasmid, as follows: 
(a) EGFR-NTEV-tcs-GV, GRB2-CTEV 
(b) EGFR-NTEV-tcs-GV, SHC1-CTEV 
(c) EGFR-NTEV-tcs-GV, PIK3R1-CTEV 
(d) EGFR-NTEV-tcs-GV, SH2(SHC1)-CTEV 
(e) ERBB3-NTEV-tcs-GV, ERBB2, GRB2-CTEV 
(f) ERBB3-NTEV-tcs-GV, ERBB2, SHC1-CTEV 
(g) ERBB3-NTEV-tcs-GV, ERBB2, PIK3R1-CTEV 
(h) ERBB3-NTEV-tcs-GV, ERBB2, SH2(SHC1)-CTEV 
(i) ERBB4-NTEV-tcs-GV, GRB2-CTEV 
(j) ERBB4-NTEV-tcs-GV, SHC1-CTEV 
(k) ERBB4-NTEV-tcs-GV, PIK3R1-CTEV 
(l) ERBB4-NTEV-tcs-GV, SH2(SHC1)-CTEV 






Fig. S11. Lapatinib and WZ4002 reduce p-EGFR (Y1068) and p-ERBB4 (Y1284) levels in A549 cells and 
T-47D cells. 
Starved cells were treated for 1 h with increasing concentrations of lapatinib (a, b) or WZ4002 (c, d) 
and stimulated for 5 mins with 30 ng/ml EGF (a, c) or 10 ng/ml EGFld (b, d) where indicated. Lysates 





Fig. S12. Spironolactone inhibits ERBB receptor activities using the universal SH2 domain adapter in 
the split TEV recruitment assay. 
Antagonist dose–response split TEV recruitment assays using spironolactone (a–c) and canrenone (d–
f), which were both applied at increasing concentrations as indicated. EGFR (a, d), ERBB2/ERBB3 (b, 
e), and ERBB4 (c, f) split TEV recruitment assays were performed in PC12 cells using the SH2 domain 
adapter SH2(GRB2). Agonists EGF and EGF-like domain (EGFld) were applied at constant 
concentrations as indicated. For each assay, plasmids encoding a receptor and an adapter, were co-
transfected with a 10xUAS-minCMVp-driven firefly luciferase (Fluc) reporter plasmid, as follows: 
(a) EGFR-NTEV-tcs-GV, SH2(GRB2)-CTEV 
(b) ERBB3-NTEV-tcs-GV, ERBB2, SH2(GRB2)-CTEV 
(c) ERBB4-NTEV-tcs-GV, SH2(GRB2)-CTEV 
(d) EGFR-NTEV-tcs-GV, SH2(GRB2)-CTEV 
(e) ERBB3-NTEV-tcs-GV, ERBB2, SH2(GRB2)-CTEV 
(f) ERBB4-NTEV-tcs-GV, SH2(GRB2)-CTEV 











ERBB4 IGF1R MET 
Control 0.4756 0.1443 0.9645 0.790 0.3153 
GRB2 0.0137 <0.0001 <0.0001 0.0016 0.0002 
SHC1 0.0005 0.0003 0.0006 0.0004 0.0406 
PIK3R1 0.0032 <0.0001 0.0064 <0.0001 0.0017 
SH2(GRB2) <0.0001 <0.0001 <0.0001 <0.0001 0.0004 
SH2(SHC1) 0.0390 0.0048 0.0182 0.0716 0.0009 
SH2(PIK3R1) 0.1228 0.0207 0.1822 0.0042 0.0897 
SH2(mix) 0.0079 0.0088 0.7840 0.0224 0.8422 
The unpaired t-test was run using GraphPad Prism (version 5). 
 
 
Table S2. Calculated sizes of fusion proteins.  




















Table S3. IC50 and pIC50 values for lapatinib obtained from dose–response split TEV recruitment 
assays as indicated. 
Receptor-NTEV-tcs-GV 
Adapter-CTEV 
EGFR ERBB2/ERBB3 ERBB4 
IC50 [µM] pIC50 IC50 [µM] pIC50 IC50 [µM] pIC50 
GRB2 2.791 
 
5.55 0.747 6.13 9,005 5.05 
SHC1 4.561 
 
5.34 0.062 7.21 4.275 5.37 
PIK3R1 0.730 
 
6.14 0.020 7.70 0.321 6.49 
SH2(GRB2) 0.305 6.52 0.072 7.14 0.166 6.78 
SH2(SHC1) 2.511 
 





Perspective and discussion 
In the first publication, we developed an assay system to monitor ERBB4 activity relevant for 
NRG1-ERBB4 signaling, which is implicated in SZ. In a drug repurposing screening approach, 
spironolactone was identified as ERBB4 antagonist. It’s efficacy to reduce ERBB4 activity was 
validated biochemically by means of phosphorylation in heterologous human cells and in 
transgenic mice in vivo. Functionally, spironolactone’s antagonistic effect was validated using 
electrophysiology. The study provides a proof of principle for targeting the NRG1-ERBB4 
pathway and using a drug repurposing screen, a strongly demanded strategy for drug 
development in psychiatric diseases (Insel, 2012). Currently, spironolactone is evaluated in a 
clinical trial as a novel treatment option for patients with schizophrenia mainly targeting the 
cognitive alterations (Hasan et al., 2020). 
In the second publication, we developed a universal RTK adapter for the cell based split TEV 
assay. The new adapter consists of three concatenated SH2 domains from GRB2 termed 
SH2(GRB2), a well-characterized RTK adapter protein. The SH2(GRB2) showed a higher signal-
to-noise ratio and performed best in dose response assays using agonists and antagonists. 
Dose response assays, especially when cell-based, are important to validate the concentration 
needed for a drug to be effective. The potency of an antagonist is mostly shown as inhibitory 
concentration of 50% (IC50), the resembling the concentration of a compound where it inhibits 
50% of the stimulated signal. The agonist counterpart is called excitatory concentration 50% 
(EC50).  
When different targets are monitored the selectivity of a tested drug can be compared using 
the IC50 and IC80 values.  During drug development, efficacy, selectivity, and safety reasons are 
major objectives for drug discovery campaigns. Within a cell the drug has a variety of potential 
interaction partners, with unintended interactions leading to undesired and effects of the 
compound (Huggins et al., 2012). The selectivity a drug shows towards its intended target 
compared to related and non-related targets contributes to its efficacy. Cell-based assay with 
a baseline reporter control can be used as a toxicity screen within an assay, giving additional 
information about the cell viability when a certain compound concentration is present. In cell-
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based multiplexed profiling assays efficacy, selectivity and toxicity can therefore be addressed 
within one assay. 
Multiplexed assays for profiling receptor activities and physiological signaling 
To test the selectivity of ERBB4 antagonists on other members of the ERBB receptor family, 
the split TEV assay was newly designed to use the same universal adapter for all ERBB receptor 
assays. However, instead of using a luciferase read-out, a molecular barcode as an RNA 
reporter that is transcribed upon GV binding was introduced. (Fig. T5). This made it possible 
to measure multiple receptor activities in parallel, making the result more comparable and 
vastly reducing the number of samples used, as multiple assays are combined within one well. 
Additionally, related (e.g. the ERBB family) and non-related (e.g. HTR2A) receptors can be 
tested in one measurement, comparing selectivity between various potential targets within 
the cell. 
In more detail, individual cell populations were transfected with one receptor (NTEV) 
construct, the SH2(GRB2) CTEV construct, and three barcode reporters, which therefore 
indicate the activity of one given receptor. For each receptor one cell population was 
transfected using a different set of barcodes (Fig. T5 A). Furthermore, one cell population was 
transfected with a set of reporters only to control for cell viability and other effects that the 
experiment conditions might have on barcode reporter expression (Fig. T5 B). Additionally, all 
cell populations were transfected with pathway sensors encoding an early growth response 
protein 1 promoter (EGR1p) and the cAMP response element (CRE), both linked to unique 
barcode reporters. These pathway sensors respond to altered mitogen-activated protein 
kinase (MAPK) (EGR1p sensor) and cAMP/calcium signaling (CRE sensor) and were described 
in more detail in (Herholt et al., 2018). The transfected cell populations are mixed and plated 
(Fig. T5 C), testing conditions are thus applied to all cell populations at once, reducing sample 
numbers and increasing the amount of data obtained from one sample (Fig. T5 D). The activity 
of each receptor and relevant physiological cellular signaling is measured simultaneously and 
therefore allows for assessing compound selectivity and potential detrimental cellular effects, 
including toxicity. Figure T5 E shows the timeline of a typical profiling experiment, starting 
with individual transfections similar to the transfection in (Wintgens et al., 2019) per receptor, 
cell populations are subsequently mixed and plated together. Cells are allowed to attach to 
the plate over night for about 14 hours and are then starved (2%FCS instead of 10% in the 
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maintenance medium) for another 14 hours. After the starvation phase antagonists are added 
as a pretreatment, followed by the agonists one hour later. Finally, the cells are lysed, the RNA 
is purified, and then subjected by next generation sequencing. Barcode frequency is then 
bioinformatically analyzed and graphically visualized. 
Figure T5: Schematic overview of the profiler experiment. (A) Individual cell populations are 
transfected with a receptor (NTEV), an adapter (CTEV), 10xUAS barcode reporters, and the 
pathway sensors EGR1p and CRE. (B) 10xUAS barcode reporters and pathway sensor are 
transfected only to serve as cell population control. (C) Mix and plate approach for 
multiplexing: individual cell populations with one receptor each are mixed, plated into wells, 
and treated under defined conditions (D). (E) Timeline of a profiler experiment.  
Agonist treatment of the ERBB family and HTR2A 
Receptor activation was tested in PC12 cells by applying the ERBB agonists EGF (specific for 
EGFR) and EGF-like domain (EGFld, specific for ERBB3 and ERBB4) as well as the HTR2A agonist 
serotonin within a concentration range of 0.1 pM to 30 nM (Fig. T6) to the transfected 
receptors EGFR, ERBB3 (co-transfected with ERBB2 for heterodimer formation), ERBB4, and 
HTR2A. As described, the pathway sensors ERG1p and CRE were also transfected into each cell 
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population. The panel is completed by the 10xUAS only control for monitoring cell viability 
and for normalizing barcode expression among individual wells. (Fig. T5B). When EGF was 
applied to the cells in this multiparametric assay, only the EGFR is activated (Fig. T6). 
Conversely, when the cells were treated with EGFld, ERBB3 and ERBB4 was activated, but 
EGFR was not. The results of individual dose response assays using molecular barcode 
reporters are consistent with the data obtained with luciferase assays shown in my previous 
work (Wintgens et al., 2019). For both EGF and EGFld treatments, the EGR1p sensor is 
activated, which is also consistent with the literature, as all ERBB receptors are known to 
activate the MAPK pathway (Nakakuki et al., 2008). As expected, neither the HTR2A receptor 
nor the CRE sensor responded to EGF or EGFld treatment. However, when the cells were 
stimulated with serotonin only CRE and HTR2A responded. The non-responsive control 
10xUAS verified that the activities monitored in this multiplex assay are due to specific 
activation of targets (i.e. receptors) and pathways. In conclusion, the multiplexed assay setup 
presented allows that multiple receptor activities and downstream physiological signaling can 
be simultaneously monitored at dose response. Notably, I did not observe any cross activation 




Figure T6: Profiles of agonist induced receptor activities obtained from multiplexed assays. 
Heatmaps of barcoded assays monitoring receptor and pathway sensor activities. PC12 cells 
were stimulated for 6h with EGF, EGFld, and serotonin in a concentration range of 0.1pM to 
30nM respectively. Plotted are fold changes referenced to a non-stimulated condition. Note 
that both heatmaps are based on data from one experiment. The heatmaps were split to 
better indicate the different fold changes for serotonin vs. EGF and EGFld treatments. 
 
Antagonist treatment of the ERBB family and HTR2A 
Next, the multiplexed receptor profiler was tested with known antagonists to demonstrate 
the feasibility of the approach. To do this, PC12 cells were transfected with the described 
receptor and pathways sensor panel. Cells were then treated with increasing concentrations 
from 0.1 pM to 30 nM of lapatinib, afatinib, WZ4002, erlotinib, AG1478, and gefitinib, all 
known inhibitors of the ERBB receptor family. After 1 hour of antagonist pretreatment, cells 
were stimulated using a mixed stimulation of 30 ng/mL EGF, 10 ng/mL EGFld, and 0.7µM 
serotonin (Fig. T7). The results for lapatinib and WZ4002 are highly consistent with previously  
obtained data from standard luciferase assays (Wintgens et al., 2019). In general, all ERBB 
receptors respond to the treatment, while, as expected, the HTR2A receptor was not inhibited 
by any of the ERBB antagonists. Afatinib, the only covalently binding antagonist, showed an 
inhibition already at very low concentrations, but induces toxicity at higher concentrations 
from 3nM and over, a finding that can be seen in the 10xUAS control panel. Thus, suggestive 
inhibition by afatinib at higher concentrations is linked to cellular toxicity rather than reduced 
receptor activity. Most inhibitors tested in this multiparametric assay system showed 
selectivity for ERBB3 or ERBB4. Thus, it was important to test whether the readout of this 
assay system is not biased towards these two receptors but can also reliably indicate a 
compound’s selectivity for EGFR. Therefore, we included AG1478, which was previously 
reported to be an EGFR selective antagonist (Levitzki and Gazit, 1995), a result that we were 





Figure T7: Profiles of antagonist induced receptor activities obtained from multiplexed assays. 
Heatmaps of multiplexed barcode-based measurement of receptor activity stimulated with 
EGF (30ng/mL), EGFld (10ng/mL), and serotonin (0.7µM). ERBB family antagonists lapatinib, 
afatinib, WZ4002, erlotinib, AG1478, and gefitinib were applied in increasing concentrations 
from 0.1pM to 30nM. The inhibition of receptors is shown in percent referenced to fully 
stimulated samples.  
Extracted from the previous data set of ERBB antagonists, the results of lapatinib and AG1478 
mediated inhibition are shown as dose response curves to clearly display the selectivity (Fig. 
T8). Lapatinib is selective for ERBB3 and ERBB4, with a 5-fold selectivity over EGFR. The 
inhibition varies for lower concentrations and in the total reduction of activity. AG1478, 
however, inhibits EGFR with an IC50 value of 0.122 µM, while ERBB3 and ERBB4 show 122-fold 




Figure T8: Barcoded reporter assays using split TEV for a dose response analysis of lapatinib 
(A) and AG1478 (B) using a constant stimulus mix EGF (30ng/mL), EGFld (10ng/mL), and 
serotonin (0.7µM). Data for EGFR are plotted in green, for ERBB2 and ERBB3 in blue, and 
ERBB4 in red. Dose response curves were calculated using the R script published in (Wintgens 
et al., 2019). Error bars are shown as SEM, with six replicates per condition.  
 
Pathway sensor responses to antagonist treatments  
The pathway sensors monitor the physiological signaling of the cell by means of transcription 
factor activities that represent endpoint of cellular signaling cascades. In detail, MAPK 
pathway and cAMP signaling pathway activities are assessed by the EGR1p sensor and the CRE 
sensor, respectively (Fig. T9). Inhibition of ERBB family receptor leads to a reduced MAPK 
signaling, which is in line with the data for all antagonists applied. Again, afatinib showed a 
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reduction in the signal already at low concentrations, consistent with the results obtained for 
monitoring receptor activity (Fig. T7). As all samples were also treated with 0.7µM serotonin 
that was present in the stimulation mix, the CRE sensor was activated to baseline levels. 
Notably, the signal was further increased by adding ERBB3 and ERBB4 selective inhibitors. 
However, EGFR selective AG1478 did not increase the signal of the CRE sensor further.  
 
Figure T9: Heatmap of pathway responses of EGR1p and CRE sensors upon antagonist 
treatment. Lapatinib, afatinib, WZ4002, erlotinib, AG1478, and gefitinib were applied in 
increasing concentrations from 0.1pM to 30nM. Inhibition of EGR1p is plotted in blue as 
percent referenced to EGF (30ng/mL), EGFld (10ng/mL) and serotonin (0.7µM) stimulated 
samples. Activation of CRE is plotted in orange as log2 transformed fold changes referenced 
to the same stimulated samples.  
 
Discussion 
Using this multiparametric profiler approach it is possible to measure activities of multiple 
receptors and downstream pathway activities in one experiment by using barcode reporters 
as a read out. The stimulation was demonstrated to be selective for the respective receptors 
(Fig. T6). Additionally, the pathway sensors that are either clustered cis elements to monitor 
cAMP/calcium signaling (CRE sensor) or an enhancer sequence of a MAPK pathway-indicative 
gene (EGR1p sensor) are activated accordingly. Previously reported inhibition of the ERBB 
receptor family was reproduced, with selectivity according to literature (Fig. T7) (Davis et al., 
2011; Levitzki and Gazit, 1995; Wintgens et al., 2019). The EGR1p sensor showed that the 
MAPK pathway is downregulated by all ERBB inhibitors. The CRE sensor, however, was 
upregulated by all antagonists applied, but not by the EGFR selective antagonist AG1478 (Fig. 
T9). As the CRE sensor is already induced to baseline levels by the 0.7µM serotonin that is 
present in the stimulation mix, which is therefore also present in the reference samples, the 
detected increase in CRE activity is on top of the initial serotonin induction. As all receptor 
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transfections contain the same 3 CRE barcode reporters it is not possible to distinguish the 
signals induced by the various receptors. Therefore, future profiler experiments should be 
equipped with individual barcodes for each receptor transfected into a cell population. For 
example, when using three receptors and one control (as depicted in Fig. T5), three barcode 
reporters each for CRE and EGR1p sensors will be needed for every receptor. 
The profiling approach presented here provides several benefits: (I) within one experiment 
activities of various targets and pathways can be measured in a cell-based assay format. The 
effects of several ligands and antagonistic compounds can be simultaneously studied in this 
multiparametric assay approach. The barcoded reporter system produces large data sets from 
multiple wells, which contrasts the separate measurement for each receptor compound 
combination in standard luciferase assays. Therefore, the profiler approach may provide an 
advantage in early drug discovery where compounds have to be screened against multiple 
targets and in multiple conditions (i.e. varying concentrations). (II) The mix and plate platform 
described in figure T5 is highly scalable and flexible regarding receptors, pathway reporters, 
and the ligands used in each experimental setup. Additionally, a unique identifier is part of 
every primer sequence given to each well to extract the RNA, subsequently the samples can 
be processed together, reducing workload and costs further. When sequencing, the unique 
identifier makes it possible to discriminate which barcode was extracted from what well. (III) 
The system could be further improved with respect to robustness and sensitivity by using cell 
lines that stably express the equivalent of the shown individual transfected cell populations. 
Especially, expression levels of targets, e.g. applying closer to endogenous expression levels, 
could be better controlled by using an inducible and stable cell line system. These stable cell 
lines then could also be mixed and plated as described. (IV) The profiler may also be performed 
in primary cells or human disease models derived from human induced pluripotent stem cells. 
To do this, the components of the assay, i.e. the receptor-NTEV-tcs-GV, adapter-CTEV, and 
barcoded reporters need to be made available as lentiviruses to guarantee efficient infection 
of target cells. (V) Many cancer mutations lead to a distorted signaling of certain receptors. To 
inhibit the signaling of the mutated, but not the still needed non-mutated version of these 
receptors selectively would lower side-effects of cancer drugs (Arteaga and Engelman, 2014). 
With our assay this comparison can be done within one measurement, additionally screening 
the cell viability. 
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(VI) Physiological signaling of the cell, either regular or altered, can be measured 
simultaneously when using the pathway sensors described above. The panel of pathway 
sensors can be expanded, for example to sensors of calcium signaling, proliferation, and 
immune pathways (Herholt et al., 2018). Additionally, pathway sensors may be assigned 
through their barcode reporters to single receptors (individual cell populations) to also track 
cellular pathway signatures induced by each receptor. Finally, the panel of receptors screened 
is flexible and thus could cover a greater variety of biological targets. Many compound 
campaigns fail late in the process due to unexpected side effects of the drug impacting 
important cellular targets. Expanding the profiler to cover a panel of these targets could help 
discover compounds that are at risk of a late stage drop out (Bowes et al., 2012). 
In summary, the flexible and robust profiler technology and the combined acquisition of 
receptor activity and pathway signatures modulated by compounds may provide a valuable 
tool to promote early drug discovery. The selectivity, efficacy and toxicity of drug candidates 
could be pre-assessed before going into the animal model. The approach would therefore be 
complementing the biochemical, computational approaches, and transcriptomic approaches 
used in drug discovery to date (Chen et al., 2017; González-Maeso et al., 2003; Subramanian 
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